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The pathogenesis of epithelial ovarian cancer is complicated by its diagnosis 
during the latter stages of the disease resulting from lack of symptoms or from presence 
of symptoms that mimic other conditions.  Because of the often fatal prognosis by the 
time of actual detection, efforts are being made to better understand the host immune 
response to ovarian cancer.  In this study, the contributions of the humoral immune 
response were investigated by focusing on the role of tumor-derived exosomes and their 
ability to modulate humoral immune responses. First, ovarian cancer patient-derived free 
circulating antibodies were investigated for immunoreactivity to patient antigen. The 
immunoreactivity allowed for the mass spectrometry identification of six proteins which 
have been shown to be correlated with cancer pathogenesis. The identity of these 
proteins were confirmed by immunoreactivity of patient-derived antibodies with 
recombinant proteins and their presence on in vivo  and in vitro ovarian tumor-derived 
exosomes (TDE) was defined.  Analysis of the TDE demonstrated bound tumor-reactive 
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immunoglobulin (predominantly IgG1 and IgG2) that exhibited immunoreactivity with the 
identified antigens.  Direct effects of the TDE on the B cell were investigated by 
coculture of B cells with patient TDE at different concentrations and time points. 
Surprisingly, B cells were induced to undergo apoptosis, with the greatest cell death 
seen at the latter time points and with the higher concentrations of exosomes. Apoptosis 
as the mechanism of cell death was confirmed by Western blot analysis with common 
apoptotic markers, PARP and caspase-3, and DNA fragmentation analysis using 
agarose gels.  Further analysis of the supernatant from the B cell/TDE cocultures 
revealed increases in three proteins (PAI-1, IL-16, and sICAM-1).  Collectively, data from 
this study suggests that ovarian patient-TDE express immunogenic antigen that binds 
IgG as a mechanism to divert the humoral antitumor response away from the tumor, 
while utilizing different subclasses to mediate strength of the antitumor response. 
Furthermore, ovarian patient-TDE induce apoptosis of B cells to diminish production of 
antitumor antibodies and promote secretion of proteins to assist the ovarian tumor in 
immune escape and promote its survival.
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IMMUNOPHYSIOLOGY OF EPITHELIAL OVARIAN CANCER  
AND THE TUMOR MICROENVIRONMENT 
 
Epithelial Ovarian Cancer 
Recognized as one of the most common malignancies worldwide [1], epithelial 
ovarian cancer (EOC) remains the 5th leading cause of cancer death among women [2] 
and in the United States, stands as the leading cause of gynecologic cancer death [3].  
Approximately, 21,980 U.S. cases are reported each year, with 14,270 estimated deaths 
[4].  From 2006-2010  reduction in mortality rates were documented  in younger ( <65 
years) and older (>65 years)  women (2.8%, 1.7 % respectively)  [5], which provides 
promise for improved future outcomes. Presently, the origins of ovarian cancer are 
undefined, but studies suggest that a number of factors contribute to increased or 
decreased risk for pathogenesis.   Anatomically, the ovarian surface is surrounded by a 
squamous/cuboidal layer of pelvic mesothelium  (called the ovarian surface epithelium—
OSE) which aids in the import/export of materials in the peritoneal cavity and assists with 
rupture and repair of the ovary during cycles of ovulation [6]. The promotion of ovulatory 
repair mechanisms enhances ovarian cell susceptibility to mutations and subsequent 
malignancies [7, 8]. This hypothesis, known as incessant ovulation [7],  has been 
validated by the relationship of the number of lifetime ovulations to risk of disease [9]. 
Studies indicate that decreases in factors such as: the number of full-term pregnancies, 
cycles of lactation, and usage of oral contraceptives are all related to decreases in 
ovarian cancer [10-12].  Other risk factors in ovarian oncogenesis 
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include excessive hormonal secretion ( e.g. gonadotropins [13] and 
androgens/progestins [14]), inflammation [15], and heredity [9].  Increases in follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) concentration during ovulation 
promotes follicle maturation and ovarian cell division and proliferation, which heightens 
the chances of mutations and malignant transformation [13].  Additionally, the 
concentration of androgens increase within the follicle [16]  which upregulates ovarian 
androgen receptors and stimulates OSE proliferation [17].  Conditions displaying 
increased levels of circulating androgen (e.g.  polycystic ovarian syndrome) have been 
shown to be associated with increased risk of EOC [18], although the evidence linking 
androgen exposure to malignant transformation is variable.  Inflammation has been 
postulated to augment the risk of ovarian cancer through ovarian tumor cell release of 
pro-inflammatory cytokines [19], prostaglandins to promote ovarian tumor cell 
invasiveness [20, 21],  and OSE disruption resulting in the formation of inclusion cysts 
which favor differentiation towards a carcinogenic phenotype  [22].  Of all the risk factors 
associated with ovarian carcinogenesis, heredity has the most compelling impact [23].  
Women who have had multiple relatives diagnosed with ovarian cancer or who have had 
a relative diagnosed prior to 50 years of age display the greatest risk [24].  Inherited 
mutations in the autosomal dominant genes, BRCA1 and BRCA 2, have a strong 
association to familial breast and ovarian cancer [25]. Studies of high risk families 
revealed that the ovarian cancer risk for a woman who has both the familial history and 
the BRCA1 mutation ranges from 32-84%, with lower probability for BRCA2 [26, 27].  
The complexity of ovarian cancer is enhanced by its heterogeneity [28] 
demonstrated through the presentation of numerous histological subtypes [29] . The 
most common EOC subtypes are serous, endometrioid, clear cell, and mucinous [30] 
and are categorized by their primary pattern of differentiation [31].  Further discrimination 
between the EOC subtypes is established through their correlation with different 
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molecular oncogenetic events [32, 33] and with the stage of disease in which early 
stages are predominantly nonserous [34] and advanced stages are commonly serous 
[35]. There are two staging systems used in classification of ovarian cancer: 1) 
Tumor/Lymph Node/Metastasis (TNM) method and the 2) International Federation of 
Gynecology and Obstetrics (FIGO) system [36].  The TNM system describes the extent 
of the primary tumor (T), the presence or absence of metastasis to nearby lymph nodes 
(N), and the presence or absence of metastasis to distant organs (M) [37]. TNM staging 
includes the letters (T, N, or M) followed by a number (0-4) which indicates increasing 
severity or an X which indicates that the information could not be assessed [38]. The 
FIGO system evaluates the pathological and/or clinical spread of the tumor and 
classifies the results into 4 stages [39], which are further subdivided (A, B, C) to reflect 
specific biological, clinical, or pathological prognostic factors within each stage [40].  
Both systems are used in classification of ovarian carcinomas and display great 
similarity,  but FIGO does not contain a “0” classification (which indicates borderline or 
low potential for malignancy)  and is most frequently used by gynecologic oncologists 
[41].  The staging procedure is performed through exploratory laparotomy in which the 
abdominopelvic organs are examined and the omentum, diaphragm, neighboring lymph 
nodes, and peritoneal fluid are sampled for evidence of cancer [42].  Stage 
classifications include: Stage I (tumor confined to ovaries), Stage II (tumor involves 1 or 
both ovaries with pelvic extension), Stage III (tumor involves 1 or both ovaries with 
cytologically/histologically confirmed spread to the peritoneum outside the pelvis, and/or 
metastasis to the retroperitoneal lymph nodes), and Stage IV (distant metastasis, not 
including metastasis in peritoneum) [43].  The metastatic nature of ovarian cancer can 
be attributed to the exfoliation of the ovarian surface, which releases tumor cells that can 
implant on the peritoneal surface [44] and adjacent organs [45], and/or integrate into the 
peritoneal fluid for transport throughout the peritoneal cavity [45]. Since no anatomical 
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barrier exists between the ovary and other abdominopelvic organs [44], the entire 
peritoneal cavity is susceptible to metastatic lesions, designating the peritoneal cavity as 
the preferred site of metastasis [45].  Dissemination into the peritoneal cavity is generally 
followed by formation of ascites [45].  Under normal physiological conditions, capillary 
dynamics allow for the constant filtration of fluid into the peritoneum (to lubricate the 
serosal surfaces) and its partial reabsorption through the lymphatic channels of the 
diaphragm to eventually reunite with the blood circulation [46].  However, when 
peritoneal dissemination occurs, fluid accumulates (resulting from enhanced vascular 
permeability and lymphatic obstruction) [46, 47] and creates an imbalance in the rate of 
reabsorption, which leads to ascites formation.  The presence of malignant ascites is 
one of the general symptoms detected upon initial diagnosis [48] and can be presented 
in early stages (stage IC and IIC), but is most often seen in advanced disease (stage III 
and IV) [43].     
The pathogenesis of ovarian cancer is further complicated by the latent diagnosis 
[49], the unknown time requirement for the developmental period of invasive disease 
[50], and the decreased reliability of early detection methods [51].  Unfortunately, EOC is 
generally diagnosed at latter stages because of the lack of symptoms or presence of 
symptoms that could be indicative of other conditions (e.g. abdominal, gastrointestinal, 
urinary, pelvic) [52].  Current approaches for detection include a physical examination to 
detect the presence of a pelvic mass [53] , and serum screening for cancer antigen 125 
(CA-125) in conjunction with transvaginal ultrasonography (TVUS) [50] to detect 
changes in ovarian size and structure. Although serum levels of CA-125 are found to be 
elevated in 90% of advanced epithelial cancer patients [54], 50% of stage I patients also 
present elevated levels [55-57].  The nonspecificity of CA-125 [55, 56] and the 
subsequent variation in interpretation, scoring, and sensitivity of TVUS [58] warrants the 
discovery of specific biomarkers and /or detection methods with enhanced efficacy.  
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The Tumor Microenvironment and Humoral Immune Responses 
The tumor microenvironment consists of the tumor and its surrounding 
extracellular matrix, extensive vasculature, various proteins, and a variety of cellular 
components.  Because of its dynamic nature, the tumor microenvironment continuously 
evolves, resulting in alterations in the tissue, alterations in the metabolic capabilities of 
the tumor, and in the recruitment of cells to the microenvironment [59].  These 
components interact with surrounding cytokine signals  [60] to generate the functional 
paradox of the tumor microenvironment manifested through the promotion of 
antitumorigenic vs. protumorigenic responses.  This paradox forms the foundation  of the 
cancer immunoediting hypothesis which emphasizes the tumor-destroying  and tumor-
promoting functions of the immune system [61]. Antitumor responses are important for 
resistance of tumor growth and the eventual elimination of the tumor. As  a key 
component in cancer immunosurveillance, elimination works in conjunction with the 
tumor suppressor mechanisms that are intrinsic to the cell [62].  Utilizing both innate and 
adaptive responses, the mechanism of elimination collectively recognizes and presents 
tumor antigen, recruits innate immune cells into the tumor [63, 64], and generates tumor 
antigen-specific T cells [65] which home to the tumor and contributes to tumor 
destruction [66].  In consideration of the adaptive immune responses, elimination of the 
tumor primarily occurs through cell-mediated immunity [67]. However, humoral antitumor 
responses have been documented to occur.  In the humoral antitumor response, specific 
antibodies are produced against tumor antigen [68], and may kill the tumor by 
complement-dependent cytotoxicity (CDC; complement protein C1q binds Fc portion of 
antibody bound to antigen to trigger complement cascade) or antibody-dependent 
cellular cytotoxicity (ADCC; immune effector cells bind Fc portion of antibody bound to 
antigen via Fc receptors and mediate cytotoxicity) [69].  Immunogenic tumor antigen 
may be tumor-specific (unique to cancer cells) or tumor-associated (differential 
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expression between cancer cells and normal cells) [70] and its expression may be 
initiated by increases in the immunogenicity of self antigen [71] resulting from DNA 
mutation (causing subsequent mutation in protein), protein overexpression, and/or 
protein post-translational modification [72]. Humoral immune responses against a variety 
of extracellular and cellular proteins have been documented in multiple cancers [73].  
Free and immune-complexed natural antibodies to human MUC1 (a primary mucin in the 
ductal cell surface of normal glandular cells) have been identified in the circulation of 
breast cancer patients [74]. Autoantibodies against p53 have been documented in 
increased levels in gastric [75] and ovarian cancers [76]. In these aforementioned cases, 
the enhancement of antibodies correlated with a positive prognosis.  However, other 
humoral response studies to tumor antigen such as: NY-ESO-1 (in prostate cancer [77]), 
p53 (in breast [78], colorectal [79, 80], vulvar [81] and ovarian [82, 83] cancers), and 
MUC5AC (in colorectal cancer [84]), indicated associations with poor prognoses. The 
variation in prognoses and recognition of tumor antigen contributes to the complexity in 
understanding the role of autoantibodies in the humoral antitumor response. 
Those tumor cells that are not eradicated by the antitumor response may enter into 
equilibrium, the second phase of cancer immunoediting which involves the immunologic 
control of cellular outgrowth [61] and the “sculpting” of cells to produce new tumor 
variants [85] to result in dormancy of the tumor [61]. In the event that these tumor 
variants successfully evade innate and adaptive immunological defenses [85], they may 
transition into the escape phase (the third phase of immunoediting [86]), as a 
consequence of tolerance induction [87] , host immune modifications in editing the 
tumor, or enhanced immunosuppression in the tumor microenvironment [61].  
Modifications in the edited tumor target may range from decreased antigen recognition 
(e.g. loss of major histocompatibility complex (MHC I), loss of antigen processing) [61] to 
promotion of anti- apoptotic mechanisms (e.g. constitutive activation of STAT3 to 
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promote high levels of Bcl-xL [88]), which collectively promote survival of the tumor 
variants. Generation of an immunosuppressive tumor microenvironment can be 
facilitated through tumor cell-immunosuppressive cytokine release (e.g. vascular 
endothelial growth factor (VEGF) [87],  tumor growth factor- beta (TGF-) [89], 
indoleamine 2,3-dioxygenase (IDO) [90]) to inhibit dendritic and T cell effector function, 
recruitment of suppressive cellular populations (regulatory T cell (Treg) and myeloid-
derived suppressor cell (MDSC)) [91] to inhibit host antitumor responses, and chronic 
inflammation (resulting in continuous generation of pro-inflammatory factors) [92, 93] to 
disrupt host immune cell responses and signal transduction pathways [94].  The 
heterogeneity of the tumor microenvironment provides a complex, yet ideal setting for 
intercommunication between the cellular, stromal, and environmental components of the 
host in order to regulate and promote tumor progression. Continuous 
intercommunication is necessary in order to ensure productive growth and dissemination 
of the tumor [95]. Emerging evidence suggests that tumor-derived exosomes (TDE) are 
key contributors to intercommunication and are involved in both evasion of antitumor 
responses and promotion of protumor responses.  
Tumor-Derived Exosomes and their Role in Modulation of the Tumor 
Microenvironment 
 
Exosomes are endosome-derived nanovesicles secreted from a number of 
different cell types including immune cells (mast cells, [96, 97], dendritic cells [98], 
macrophages [99], T cells [100, 101], B cells [98, 102]), epithelial [103]  and neural 
[104]cells,  and tumor cells. The release of exosomes is acknowledged to be important 
in intercellular communication [105], and TDE have been shown to interact with their 
targets through a number of mechanisms ranging from direct stimulation of the target 
through exosome expression of surface ligands to acceptance of surface receptors from 
the tumor cell [106].  In addition to surface interactions with their target, TDE have also 
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been documented to transfer genetic information resulting in genetic transformation in 
their target [107].  The efficacy of exosomes as vehicles of intercellular communication is 
related to the three-dimensional structure of their proteins which enhances the stability of 
the exosome and protects the biological activity of the exosome protein [108].   The 
protein composition of exosomes is correlated (but not identical) to the cell from which 
the exosome is derived.   Therefore, TDE express tumor-related antigens, but are not 
molecular duplicates of the plasma membrane of their parental tumor cells. Instead, they 
represent a ‘micromap’ that displays increased expression of antigens associated with 
the tumor [109, 110].  TDE are abundantly found in plasma and malignant effusions 
derived from cancer patients [111-113], and their accumulation in malignant fluids 
appears to be instrumental in the transformation process [114].  Studies indicate that 
increased release of exosomes facilitates communication between the tumor 
microenvironment and the tumor cell [115, 116], and has been documented to contribute 
to the anti- and protumorigenic effects on the tumor.  TDE have been shown to induce 
specific antitumor responses after being exposed to stress which induced expression of 
molecules on (MHC, CD80, CD86) [117] or in (HSP70) [118] the exosome.  Utilizing their 
expression of tumor antigen, TDE have been used to pulse dendritic cells which resulted 
in cross-presentation of tumor antigen to induce CD8+T responses against the tumor 
[113].  From the humoral immune perspective, the antitumor response is demonstrated 
through the production of specific antibodies against tumor antigen [68], which is often 
correlated with poor survival [119].These antibodies may be deposited as IgG 
autoantibodies in the neoplastic parenchyma [120] or released into the circulation as free 
entities and/or associated with microvesicles/exosomes [112, 121].  Despite the 
presence of tumor-reactive IgG in the circulation of patients with various cancers 
including head and neck [122], melanoma [123], breast [124, 125], and ovarian [121, 
126, 127], an effective humoral antitumor response fails to be mounted. Protumorigenic 
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effects mediated by TDE range from regulation of tumor growth to invasion, 
angiogenesis, and metastasis [128-130] through expression of molecules such as matrix 
metalloproteinases (MMP-2, MMP-9)[131, 132] and horizontal transfer of growth factor 
receptors (EGFRvIII)[107]. Additionally, TDE have been shown to directly and indirectly 
modulate evasion of anti-tumor responses provided by effector T cells to assist in 
progression. Melanoma-derived exosomes have been shown to promote monocyte 
production of myeloid-derived suppressor cells [129] which can act to suppress T-cell 
responses [133, 134]. Ovarian TDE demonstrate induced apoptosis of T cells by 
enhanced expression of FasL on the exosomes and CD3-zeta suppression on the T cell 
[135], while nasopharyngeal TDE have been shown to express increased galectin-9 to 
induce T cell apoptosis via Tim-3 [136].  
Hypothesis and Goals 
Since the interaction of TDE with other immune cells is pleiotropic, it stands to 
reason that the TDE may also exert effects on B cells that could manipulate both anti- 
and protumorigenic constituents of the tumor microenvironment. Although it has 
previously been shown that B cells can produce exosomes that can activate T cells [102] 
and these exosomes have a number of targets including B cells [137], follicular dendritic 
cells [138], allergen-specific T cells [139], therapeutic CD20 antibodies [140], and 
cytokine-activated fibroblasts [141], little is known about the effects of TDE on B cells. A 
study conducted by Yang et al., 2012 revealed that mycoplasma-infected TDE 
preferentially activated B cells and induced robust pro- and anti-inflammatory cytokine 
production in splenic B cells [142]. However, that study focused more on the 
mycoplasma-inducing effects of the exosomes on immunomodulation. This study has 
primary interests in reasons behind the apparent, yet inefficient humoral response to 
ovarian cancer, and is proposing that TDE are exerting effects on B cells to mediate not 
only the humoral antitumor response, but also immunomodulation to support progression 
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of the tumor. Using human ovarian cancer as a model system, the hypothesis is that 
ovarian TDE compromise the functional ability of B cells to generate an adequate 
humoral antitumor response and exploit the B cell to modify the tumor microenvironment 
to support the tumor.  The main goals of this study are to investigate the role of the TDE 
in the efficacy of the humoral antitumor response and explore their impact on humoral 
modulation through 1) Characterization of the immunoreactivity of ovarian cancer 
patient-derived free antibodies and utilizing that reactivity to define ovarian tumor-
associated antigens; 2) Isolation and classification of ovarian cancer patient-derived 
exosome-associated antibodies;  and 3) Analysis of the effects of ovarian cancer patient-




IDENTIFICATION OF IMMUNOREACTIVE TUMOR ANTIGEN USING 
 CIRCULATING FREE HUMORAL RESPONSES 
 
Introduction 
In the cancer microenvironment, antigens are functionally and/or structurally 
altered by overexpression, mutation, aberrant degradation, or post-translational 
modification that makes them immunogenic [143]. In an effective immune response, 
these immunogenic proteins are detected and an antitumor response is promoted to 
eliminate the transformed precursors before they establish malignancy. Effective 
elimination is characterized by the simultaneous collaboration of innate and adaptive 
cell-mediated and humoral responses [144]. In the adaptive antitumor response, T cells 
(with cognate TCR) recognize tumor-associated antigen processed/presented on the 
MHC of antigen-presenting cells (APC)[145], along with subsequent costimulation [146] 
and cytokine expression for facilitation and maintenance of the response [147]. 
Elimination of the tumor  is accomplished through the activation of cytotoxic T (CTL) 
cells to induce tumor cell apoptosis [148], activation of CD4+T cells to promote cellular 
responses through stimulation of APC presentation of antigen [149], and promotion of 
humoral responses through activation of  B cells to produce antigen-specific antibodies 
that enhance tumor cell uptake by APCs [150]. The primary antitumor response is 
facilitated by the cellular arm of the adaptive immune system [151], however, humoral 
responses to tumor antigen are clearly demonstrated through the production of antitumor 
antibodies [152-154]. This production of antibodies is presented as elevated IgG in the 
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blood and sera [155-157].  As the most abundant plasma immunoglobulin [157], IgG is 
expressed through subclasses IgG1-IgG4, can exist in the circulation prior to detection 
of circulating antigen [143, 152, 158] and is long-lived, which allows for efficient 
opsonization of the target and complement activation against the target [157]. In ovarian 
cancer sera, levels of tumor-reactive IgG are elevated [159], suggesting intact humoral 
immunity in ovarian cancer patients and an effective humoral antitumor response. 
However, in the midst of this IgG-laden environment, ovarian tumors continue to thrive. 
A key factor in the progression of transformed cells to malignancy is the tumor 
microenvironment [160]. The tumor microenvironment consists of a number of cellular 
participants including immune cells which are critical for suppression of tumor growth 
[160]. However, the functional activities of these immune cells are often 
counterregulated by tumor cell expression and release of a number of biologic 
components [128] which act to promote the growth and metastatic progression of the 
tumor [161]. One essential biologic component in growth and progression is the tumor-
derived exosome (TDE).  Although the release of exosomes occurs in non-neoplastic 
cells, their accumulation in normal biological fluids is rare [162]. In contrast, TDE are 
abundant in malignant and pleural effusions [129, 163], but the effects of their presence 
on the survival of the tumor cell is somewhat ambiguous [164]. The majority of the 
available evidence suggests that TDE play a more active role in promoting progression 
of the tumor [164]. TDE have been documented to transfer and/or shed molecules in 
order to promote progression. TDE from mesothelioma and prostate cancer cell lines 
were found to transfer TGF-1 to fibroblasts and trigger their differentiation into 
myofibroblasts [165], which generate chemical and mechanical conditions  to encourage 
tumor progression [166].  Melanoma and liver carcinoma cells were found to release 
TDE that contain major histocompatibility chain (MHC-I) related chain ligands (MIC- A, 
MIC-B) as a means to subvert recognition by its receptor, natural killer group 2 member 
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D ( NKG2D), on natural killer (NK) and cytotoxic T (CD8+T) cells [167], thereby 
subverting cytolysis.  Another mechanism used by exosomes in tumor progression 
involves dampening the immune response against tumors.  Melanoma exosomes in the 
blood promoted the conversion of peripheral blood monocytes to myeloid-derived 
suppressor cells (MDSC) [133].  As a different means of dampening the immune 
response, ovarian cancer exosomes were shown to enhance FasL expression on their 
surface and suppress CD3-zetato stimulate tumor-reactive T cell apoptosis [135].  In 
addition, studies with melanoma TDE have demonstrated capabilities in programming 
the pre-metastatic niche and bone marrow progenitors toward a pro-metastatic, pro-
vasculogenic phenotype to support tumor growth and metastasis [168].   
Since TDE can mediate the progression of the tumor and its evasion of cellular 
antitumor responses, perhaps they may also intervene in the humoral antitumor 
response, thereby permitting further development of the tumor. Utilizing these circulating 
antitumor antibodies to identify  immunoreactive antigens may divulge proteins that are 
essential to carcinogenesis [51]. Likewise, analysis of antigens associated with TDE may 
unlock the mysteries of the existent, yet inadequate humoral response needed for 
efficient eradication of the tumor and the role of the TDE in tumor progression and the 
humoral response. We suggest that the circulating free and TDE-associated humoral 
immune response can be used to identify specific tumor-associated antigen, which in the 
context of TDE may be a mechanism for diverting the immune response from the tumor. 
Using human ovarian cancer as our model system, we investigate immunoreactivity of 
tumor-associated antigen of ovarian patient cancer cells, patient in vivo and in vitro-TDE 
antigen and patient-derived free antibodies. We establish that ovarian tumor-derived 
exosomes express tumor-associated antigen which is recognized by tumor-reactive 
antibodies, thereby indicating a role for TDE in the ovarian antitumor humoral response. 
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Materials and Methods 
Patient sera, Ascites, and Cell Lines 
Biofluids (sera or ascites) used in this study were derived from patients 
diagnosed with Stage III (T3c) serous carcinoma (designated UL-124,-167,-190,-207,-
351,-398), mucinous adenocarcinoma (UL-324), carcinosarcoma (designated UL-224), 
teratoma (designated UL-184), and serous/endometrioid mixed carcinoma (designated 
UL-472). Samples were obtained from the Gynecologic Oncology Repository at the 
University of Louisville, under an approved IRB protocol. Additional information about 
ascites sample UL-309 was unavailable. Control sera were derived from age-matched 
women with no evidence of ovarian disease. Primary ovarian tumor cell cultures were 
established from UL-124 ascites. Primary cultures were grown in 75 cm2 tissue culture 
flasks initially in Hyclone RPMI 1640 medium (ThermoScientific) supplemented with 
2mM L-glutamine, 10% fetal bovine serum (FBS, Biowest), 1mM sodium pyruvate 
(CellGro, Mediatech),  0.1 mM nonessential amino acids (CellGro, Mediatech), and 100 
units/mL penicillin-streptomycin (Gibco, Invitrogen) in a humidified incubator at 37C with 
5% CO2. After assurance of confluence, cells were transferred into Ultraculture General 
Purpose Serum-Free Media without L-glutamine, but supplemented with the same 
amount of sodium pyruvate, non-essential amino acids, and penicillin-streptomycin. Cell 
viability was evaluated by trypan blue exclusion and all cultures utilized were >95% 
viable. 
Preparation of Tumor Cell Lysates 
Prior to harvesting of cells, culture supernatant was removed and saved for 
subsequent culture exosome isolation. Cells were rinsed twice with cold Hyclone 
DPBS/Modified (ThermoScientific) and were solubilized with RIPA Buffer (1X, Pierce) 
supplemented with protease inhibitor cocktail III (100X, RPI) and phosphatase inhibitor II 
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(100X, Sigma).  RIPA-solubilized cells were kept on ice for 5-10 minutes and then cells 
were collected using a cell scraper. Solubilized cell lysate was collected into 1.5 mL 
microcentrifuge tubes (Eppendorf) and centrifuged at 14,000 x g for 15 minutes at 4C to 
pellet the cell debris. Resulting supernatant was collected and assayed for total protein 
by the Bradford assay (Bio-Rad) using bovine serum albumin (BSA) as a standard. 
Preparation of Tumor Cell Lysate for 1st Dimension Focusing  
To ensure low conductivity and reduced charged agent presence in the UL-124 
lysate, multiple samples of 100 g lysate were “cleaned up” using the Perfect-FOCUS kit 
(G-Biosciences) according to manufacturer’s instructions in preparation for isoelectric 
focusing and 2DE. Post clean-up, the protein pellets were rehydrated (according to 
manufacturer’s instructions) in 2D-Xtract Chaotropic Extraction Buffer (G-Biosciences) 
with the addition of 50 mM dithiothreitol (DTT), and 0.2% Bio-Lyte 3/10 Ampholyte (Bio-
Rad). Rehydrated protein was added to ReadyStrip Immobilized pH Gradient (IPG) 
Strips (11 cm, pH 3-10 NL, BioRad) placed into the Immobiline DryStrip Reswelling Tray 
(Pharmacia Biotech). Tray was sealed and strips were allowed to rehydrate overnight at 
room temperature. To facilitate the 1st dimension run, the Multiphor II Electrophoresis 
Unit (Pharmacia Biotech) attached to an Isotemp 1016S Refrigerated Heated 
Recirculating Waterbath was set to 20C and the protocol for 1st dimension focusing was 
followed. In short, PlusOne DryStrip Cover Fluid (Pharmacia Biotech) was added to the 
surfaces of the Multiphor II and Immobiline Strip Tray (Pharmacia Biotech). A drystrip 
aligner (GE Healthcare) was placed into the strip tray and the rehydrated IPG strips were 
placed into the aligner with the acidic end properly aligned. Two 11 cm IEF electrode 
strips (Pharmacia Biotech) were moistened with ddH2O and placed on top of the strips at 
the cathode and anode ends and covered by the electrodes. Strips were focused 16h 
16 
 
(300 V, 1h; 1400 V, 15h) using an EPS 3501XL Electrophoresis Power Supply 
(Pharmacia Biotech).  
IPG SDS-PAGE and Analysis of Immunoreactivity 
In preparation for 2nd dimension SDS-PAGE, IPG strips were equilibrated in 2 mL 
of IPG-Strip Equilibration Buffer (G-Biosciences) with 2% DTT (Research Products 
International, RPI) and incubated for 15 minutes at room temperature on a Mistral Multi-
Mixer (LabLine), low setting.  Incubation was repeated with IPG-Strip Equilibration Buffer 
with 2.5% iodoacetamide (Sigma). Criterion Tris-HCl IPG + 1 well gradient (8-16%) 
polyacrylamide gels (BioRad) were equilibrated for 10 minutes using 1X 
Tris/Glycine/SDS (TGS) buffer (10X, BioRad) on a Criterion Cell electrophoresis cell (Bio 
Rad). Post equilibration, strips were rinsed in 1X TGS buffer. An agarose sealing 
solution (G-Biosciences) was placed into the IPG well on the aforementioned Criterion 
Tris-HCl gel and the IPG strip placed into the well. Once the agarose had solidified, the 
single well was loaded with Precision Plus Protein Dual Color Standard (BioRad) and 
SDS-PAGE was carried out using the Criterion Cell and Power Pac 300 (BioRad). Gels 
were silver stained (BioRad) or subjected to Western blotting. Western blotting was 
performed using the Criterion Blotter (BioRad) and immunoreactivity patterns defined by 
probing membranes overnight at 4C with patient sera, diluted 1:250, followed by 
peroxidase-conjugated anti-human IgGAM  (1:4000, Sigma).  Dilution of sera was 
determined by serial dilution to identify the optimal dilution to distinguish seropositive 
patients and seronegative controls. Bound immune complexes were visualized by 
Immune Star HRP chemiluminescence (BioRad) and the resulting film was analyzed for 
similarity in reactivity between different sera. Bands/spots corresponding to similar 
reactivity were cut out of the silver stained gel and analyzed by mass spectrometry 
(Vanderbilt University, Nashville, TN).  
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Isolation of Tumor Cell Protein by Rotofor Fractionation 
Tumor cell lysate was desalted by column chromatography using P6 Desalting 
Gel (BioRad) and resulting protein was assayed by the Bradford method.  Desalted 
protein concentration was used to determine amount of ampholyte to combine with the 
protein sample. Desalted protein was combined with 0.5% Bio-Lyte 3/10 Ampholyte (Bio-
Rad) and ddH2O and loaded onto the Rotofor Cell (BioRad). Protein was focused for 4 h 
using the PowerPacHV (BioRad) under recirculated refrigeration. Focused proteins were 
collected into 20 fractions and the pH and protein concentration acquired for each.  50 
g protein of each fraction were loaded onto a Criterion Tris HCl 4-15% (BioRad) gel, 
electrophoretically separated, and silver stained or analyzed by Western blotting. 
Membranes were probed at 4C overnight with patient sera (1:250) followed by 
peroxidase-conjugated anti-human IgGAM (1:4000, Sigma).  Bound immune complexes 
were visualized by Immune Star HRP chemiluminescence (BioRad) and the resulting 
film was analyzed for similarity in reactivity between different sera.  Thirteen bands 
corresponding to shared immunoreactivity were cut out of the rotofor fractionated-silver 
stained gel and analyzed by mass spectrometry (Vanderbilt University, Nashville, TN).  
Mass Spectrometry (MS) Sample Preparation: In-Gel Digestion Procedure 
 Silver-stained protein gel bands were rinsed with water thoroughly to remove 
residual acetic acid. Fresh reducing reagents (30 mM of potassium ferricyanide, 100 mM 
of sodium thiosulfate) in a 1:1 ratio were mixed and immediately added in sufficient 
volume to cover the gel piece. Once the silver-brown color in each gel piece 
disappeared, the reducers were removed.  The gel slice was washed with HPLC H2O 
and 100 mM of NH4HCO3, alternatively, until the gel piece was clear.  Each gel slice was 
diced into small pieces (1 mm2) and placed into a clean tube, then washed twice with 
100 L (or enough to cover the gel pieces) of 25 mM NH4HCO3/50% ACN with vortexing 
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for 10 minutes.  The gel pieces were completely dried by Speedvac.  Dried gel pieces 
were partially rehydrated with 5 L of 100 mM NH4HCO3 and the proteins reduced in 25 
L of 10 mM DTT in 25 mM NH4HCO3 for 1 hr at 56C.  Supernatant was removed and 
discarded and proteins were alkylated with 25 L of 55 mM iodoacetamide in 25 mM 
NH4HCO3 in the dark for 45 minutes at room temperature. Gel pieces were washed 
twice in 100 L of 100 mM NH4HCO3 (with vortexing for 10 minutes), dehydrated with 
100 L of 25mM NH4HCO3 in 50% ACN (with vortexing for 5 minutes, repeated once), 
and were completely dried by Speedvac for 20 minutes.  Dried gel pieces were 
rehydrated with 5L of trypsin solution (0.1 g/mL trypsin in 100 mM NH4HCO3), and 
50-70 L of 100 mM NH4HCO3 was added until the gel pieces returned to their original 
size. Digestion was carried out overnight at 37C and then stopped by the addition of 1.5 
L of trifluoroacetic acid. The resulting peptides were recovered by two-25 minute 
extractions using 30 L of 50% ACN/5% formic acid at room temperature with 20 minute 
vortex/5 minute sonication cycles. The extracts were combined and dried in a Speedvac. 
The tryptic peptides were reconstituted in 25 L of HPLC water with 0.1% formic acid.  
Peptide separation and MS/MS analysis 
Digested peptides were separated and mass analyzed using an Eksigent Nano-
LC system connected to a LTQ Velos (Thermo Fisher Scientific) ion trap mass 
spectrometer.  Briefly, tryptic peptides were loaded onto a 150 m ID microcapillary 
fused silica pre-column, which was in-house packed with 4 cm x 5m C18 resin (Jupiter 
C18, 5 m particle size, 300Å pore size). The C18 trap column was coupled to a 
nanoflow analytical column packed with 10 cm of 3 m C18 reverse-phase resin (Jupiter 
C18, 3 m particle size, 300 Å pore size) constructed with an integrated electrospray 
emitter tip. Peptides were eluted with a 90 minute gradient (from 2%ACN with 0.1% FA 
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to 35% ACN with 0.1% FA) over 35 minutes, followed by 35% ACN to 90% ACN over 15 
minutes at a flow rate of 0.5 µL per minute. The LTQ Velos mass spectrometer was 
operated in data-dependent mode in which an initial MS scan was recorded, the mass-
to-charge range 300-2000u, and the 5 most abundant ions were selected for subsequent 
collision-induced dissociation. Dynamic exclusion (repeat count 1, exclusion list size 
150, and exclusion duration 60s) was enabled to allow detection of less abundant ions.  
MS Data Analysis  
LC-MS/MS raw files were converted into .dta files by a custom ScanSifter 
algorithm. Spectra that contained fewer than 25 peaks or that had less than 2e1 
measured total ion current were removed. DTA files for singly charged precursor ions 
were created if 90% of the total ion current occurred below the precursor ion m/z ratio 
and all other spectra were processed for doubly and triply charged ions. DTA files were 
searched against the human protein database Uniprot-human 155_200907_rev with 
20,914 total protein entries using the SEQUEST algorithm.  The search parameters used 
allowed for the following differential modifications: +57 on cysteine and +16 on 
methionine. SEQUEST-searched files (pepXML) were imported into ID Picker software 
for protein assembly. Results were filtered using the following criteria: a minimum 
peptide length of five amino acids,  a minimum of one unique peptide per protein 
(modifications to cysteines or methionines were not considered distinct from the 
unmodified peptides), overall maximum false positive rate (FDR) of 5%, a minimum of 
two additional peptides to establish a unique protein group, one protein reported per 
protein group, and single protein groups indicated by proteins that share the same set of 
peptides (indiscernible from each other based on available data).  
Verification of Mass Spectrometry-Identified Ovarian Cancer Antigen  
To verify the presence of the ovarian cancer antigen identified by mass 
spectrometry, immunoprecipitation of immune complexes was performed using Protein 
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G HP SpinTrap columns (GE Healthcare) and True Blot anti-rabbit or anti-mouse Ig IP 
Beads (eBioscience). In short, UL-124 serum-containing and serum-free lysate was 
precleared by combining 520 g lysate protein to a SpinTrap column or to 50 L of the 
anti-rabbit /anti-mouse Ig IP beads.  Lysate and beads were incubated at 4C on a 
Labquake rotisserie shaker (Barnstead Thermolyne) for 1 hour, centrifuged to acquire 
the precleared lysate, and protein concentration of precleared lysate obtained by the 
Bradford method. For SpinTrap IP: Commercial antibodies corresponding to the mass 
spec-identified antigens were conjugated to the Protein G SpinTrap matrix (20 g 
protein/column) for 3-4 hours at room temperature (with rotisserie rocking) and the 
Protein G SpinTrap cross-link protocol was followed.  Antibodies used include: GRP-78 
[rabbit polyclonal, Santa Cruz Biotechnology [SCBT], annexin 2, cathepsin D, alpha-
enolase, HSC 70, and PDI--all mouse monoclonal (SCBT). Tris-buffered saline (TBS) 
was used as an IP control.  Unconjugated antibody was removed and precleared lysate 
mixed with TBS was added to the conjugated Protein G SpinTrap beads for incubation 
overnight at 4C.  Supernatant was collected by centrifugation and the cross-link 
protocol was continued. Bound antigen was eluted using 0.1M glycine/urea as an elution 
buffer and Bradford protein assay performed. For dot blot analysis, 5 L (0.5 g) of each 
antigen sample (in duplicate) were spotted onto individual nitrocellulose membranes 
(BioRad) and allowed to air dry.  BSA (1 mg/mL) and HeLa or A431 (epidermoid 
carcinoma cell line) lysate were used as negative and positive controls respectively. 
Membranes were blocked in 5% nonfat milk/TBST, washed with 1X TBST (TBS + 0.1% 
Tween-20) and incubated at 4C overnight with corresponding commercial antibodies 
(diluted 1:1000) and control or ovarian patient sera (diluted 1:250). Secondary HRP goat 
anti-mouse/anti-rabbit (1:5000, BioRad) or peroxidase-conjugated anti-human IgGAM 
(1:4000, Sigma) was added and immunoreactivity analyzed by Immune Star HRP 
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chemiluminescence (BioRad).  For TrueBlot IP:  5 g of the aforementioned antibodies 
were added to the precleared lysate, incubated with rotisserie mixing for 3h at 4C , and 
the incubated GRP-78/lysate sample added to the True Blot anti-rabbit beads with the 
remaining Ab/lysate samples added to the anti-mouse beads for an overnight incubation 
at 4C.  Post incubation, supernatant was collected by centrifugation at 10,000 x g, 
beads were washed 3x in cold NP-40 Lysis Buffer (50 mM Tris HCl, pH 8, 150 mM NaCl, 
1% NP-40), supernatant aspirated, and beads combined with 50 L of 1 X Laemmli. 
Beads were boiled and centrifuged to collect supernatant containing the 
immunoprecipitated antigen.  Immunoprecipitated antigen samples were loaded onto 
Mini-Protean TGX Precast Gels (4-15%, BioRad), electrophoretically separated, and 
analyzed by Western blotting.  Membranes were blocked and probed overnight at 4C 
with corresponding commercial antibodies as previously mentioned. Secondary rabbit 
and mouse TrueBlot anti-rabbit/anti-mouse IgG HRP (eBioscience) was added followed 
by analysis of immunoreactivity using Immune Star HRP chemiluminescence (BioRad). 
Recognition of Recombinant Proteins by Ovarian Cancer Sera Antibodies 
To verify recognition of the mass spectrometry-identified proteins by ovarian 
cancer sera, 0.2 g human recombinant protein for GRP-78, Annexin 2, Cathepsin D, 
PDI (all from ProSpec Bio), Alpha-enolase (American Research Products), and HSC70 
(Enzo Life Sciences) were combined with 4X LDS Nonreducing Buffer 
(ThermoScientific), loaded onto a 10% SDS-PAGE gel, and analyzed by Western blot 
using sera from a non-cancer control (Ctrl, 1:250) and ovarian cancer patients [serous 
carcinoma (sample 167, 351, 398), serous adenocarcinoma (sample 190, 207), and 
mucinous adenocarcinoma (sample 324)]. All ovarian sera were used at 1:250 with the 
exception of the mucinous sample (1:100), due to lack of detection at the greater 
dilution. In addition, the recombinant proteins were probed with a mixture of commercial 
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antibodies against the identified proteins (1:1000) to further ensure detection of the 
recombinant antigen.   
Isolation of Ovarian TDE and Analysis of TDE Immunoreactivity 
Exosomes were isolated from ovarian tumor-patient (UL-124) ascites, serum-
containing and serum-free conditioned ovarian tumor culture media, patient ascites (UL-
472, UL-309, UL-316, UL-224) and a non-cancer serum control (NCC) by a two-step 
procedure developed in our laboratory [126].  In short, ascites and media (100 mL) were 
concentrated by ultrafiltration and applied to a 2% agarose (ABT) chromatography 
column (1.5 x 20 cm) equilibrated with ddH2O.  Fractions (1 mL) were collected and the 
absorbance (280 nm) of the elution was monitored. Fractions containing material greater 
than 50 million Daltons were obtained and ultrafiltrated, and the quantity of protein was 
assayed by the Bradford method.  15 g (UL-124 ascites and culture-derived) and/or 10 
g (remaining ascites) of exosome protein was mixed with 1X  Laemmli sample buffer, 
loaded on a 10% SDS-PAGE gel, and analyzed by Western blot.  Immunoreactivity of 
tumor-exosome derived protein was assayed by commercial antibodies (Santa Cruz and 
Cell Signaling Technology) corresponding to mass spectrometry-identified proteins as 
mentioned previously. 
Results 
Recognition of Ovarian Tumor Antigens by Patient Sera Antibodies 
In the initial two-dimensional gel electrophoretic (2-DE) analysis, traditional 
isoelectric focusing of ovarian tumor antigenic protein was evaluated by silver staining of 
IPG SDS-PAGE gels containing focused protein followed by Western blot with serum 
antibodies from an ovarian carcinosarcoma patient (UL-224) and an ovarian teratoma 
patient (UL-184). Bands corresponding to shared recognition between sera were 
subjected to mass spectrometry. As a comparative focusing tool to traditional IEF, 
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rotofor fractionation was used in a separate analysis, although it is typically used as a 
means of pre-fractionation to reduce complexity of crude protein.  Ovarian tumor 
antigenic protein was rotofor fractionated and the protein content of each fraction 
evaluated by silver-stain of gradient gels and subsequent Western blot with serum 
antibodies from patient UL-224 (Fig. 1A) and UL-184 (Fig. 1B). Thirteen bands (as 
indicated in figure 1) were randomly chosen for mass spectrometry analysis.  Similar 
reactivity between patient-derived antibodies to antigenic protein was noted with some 
variation in intensity (stronger recognition with UL-224: fraction 12; stronger recognition 
with UL-184: fraction 9, lower band).  
Confirmation of Ovarian Tumor Antigens by Patient Antibodies 
Mass spectrometry analysis identified multiple proteins. From the analysis, six 
proteins [GRP 78 (glucose-related protein 78), annexin 2, cathepsin D, alpha-enolase, 
HSC70, and PDI (protein disulfide isomerase)] were selected for focus due to their high 
or low protein scores, their association with tumor survival, and/or their present status as 
a potential biomarker. In order to verify the presence of these antigenic proteins in the 
ovarian cancer lysate sample, True Blot bead and Protein G SpinTrap Column 
immunoprecipitation was performed by complexing UL-124 serum-containing or serum-
free culture lysate with commercial antibodies corresponding to the proteins of interest, 
subjecting the eluted antigen to Western and dot blot, and probing with the commercial 
antibodies corresponding to the antigens of interest. For the dot blot assays, captured 
antigens were applied to the membrane in duplicate. Immunoreactivity of precipitated 
antigen for all antigens of interest were detected by dot blot (Fig. 2A) and confirmed by 
Western (Fig. 2B).  
Validation of Sera Antibody Detection Using Recombinant Proteins 
   Humoral responses in detection of GRP 78, annexin 2, cathepsin D, alpha-
enolase, HSC70 and PDI were evaluated by Western blot with sera from patients with 
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grade 3 serous adenocarcinoma/carcinoma and grade 1 mucinous adenocarcinoma. 
Using serous adenocarcinoma/carcinoma patient antibodies (Fig. 3A-E), Western blot 
identified the presence of annexin 2, alpha-enolase, and HSC70 with variations in 
intensities and isoforms between samples. Preliminary assays for antigen detection by 
serum revealed minimal detection of cathepsin D by the serous samples tested, with the 
exception of sample 351. Out of the serous carcinoma samples assayed, sample 351 
displayed lone recognition of the intermediate cathepsin D isoform (~46 kDa). 
Additionally, reactivity to isoforms of HSC70 (~30 kDa) and annexin 2 (~75-90 kDa) were 
detected in varying degrees by the serous samples. Mucinous adenocarcinoma patient 
antibodies (Fig. 3F) detected GRP78 and alpha-enolase, and faintly detected the 
intermediate form of cathepsin D (~46 kDa). Additionally, the higher molecular weight 
isoform was detected with annexin 2, as seen in some of the serous samples. A mixture 
of commercial antibodies (Fig. 3G) corresponding to recombinant proteins of interest) 
was utilized to detect viability of the antibodies and their ability to recognize the antigens 
at their standard molecular weights.  Of the 6 antigens assayed, the commercial 
antibodies recognized GRP78, annexin 2 (both isoforms), alpha-enolase, and PDI. 
Identification of recombinant antigens using serum antibodies from normal, non-cancer 
presenting controls (Fig. 3H) similarly recognized alpha-enolase and HSC70 at its 
standard molecular weight and the lower molecular weight form.  
Analysis of Ovarian Tumor-Reactive Antigens in in vivo and in vitro-derived  
Ovarian TDE 
 To determine whether ovarian tumor-derived exosomes are enriched with the 
same antigens identified by mass spectrometry of ovarian tumor cells, exosomes from 
UL-124 ascites or cell culture (with and without serum) were probed with commercial 
antibodies against the antigens of interest from the mass spectrometry analysis.  
Western blot analysis of ascites-derived and culture-derived exosomes demonstrated 
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the presence of GRP 78, alpha-enolase, PDI, and varying isoforms of cathepsin D (Fig. 
4). The presence of the cathepsin D active intermediate enzyme (~46 kDa) was detected 
in all samples, while the immature proenzyme (52-60 kDa) was detected in ascites and 
the serum-containing culture. The active mature form (~33 kDa) was detected in ascites 
only. Variation in recognition was seen between the culture-derived samples, particularly 
in the serum-containing identification of annexin 2 and HSC70, whose expression was 
shared in the ascites sample (Fig. 4). It is known that cells grown in serum-free media 
are more sensitive to factors such as pH, temperature, mechanical stresses etc., which 
can affect growth and may alter molecular expression. 
 Concern was raised over the multiplicity of bands detected in the in vivo-derived 
tumor exosomes from patient UL-124, which could suggest lack of specificity of the 
commercial antibodies used. In order to clarify presence of the tumor-reactive antigens 
in in vivo-derived exosomes, several patient-exosome samples were used and were 
probed with a different set of commercial antibodies.  Western blot analyses revealed 
the presence of annexin 2 (A2) as double bands ~38 kDa in patient samples UL-472, -
309, -124,-316 with faint recognition in patient sample UL-224 and no recognition in the 
corresponding non-cancer control (Fig. 5A). Utilizing the new anti-Enolase-1 (alpha-
enolase) antibody, however, presented an interesting result.  While the positive cellular 
control exhibited recognition at ~47 kDa (corresponding to Enolase-1), three of the 
exosome samples recognized bands at a lower molecular weight, around 30 kDa. We 
surmise that this lower molecular weight band is the isoform of enolase-1, c-myc binding 
protein-1 (MBP-1, 37 kDa) (Fig. 5B) or potentially an alternative splice variant of 
enolase-1. 
Discussion 
 Cellular proteins present in the tumor microenvironment can be functionally 
and/or structurally altered, resulting in their ability to become immunogenic and provoke 
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an autoantibody response.  These autoantibodies reflect responses to tumor-associated 
(differentially expressed on normal and cancer cells) [70] antigens and can be detected 
in the circulation regardless of the magnitude of tumor associated-antigen expression or 
tumor size [169].  As a result of the long-lived humoral response, the antigen presence is 
“amplified,” which facilitates ease in detection [170] . Since autoantibodies act as 
sentinels of aberrant cellular activity [171] and their presence reflects the execution of a 
humoral immune response to the tumor, detailed analysis of their immunoreactivity can 
provide a clearer understanding of the tumor associated-antigens that they recognize 
and their role in tumorigenesis.   
Progress in the characterization of human cancers has been attained through 
proteomic analyses of cancer-associated serum proteins [172]. Proteomic analysis 
involves extensive characterization of proteins, including identification of any 
modifications and interactions, and structural determination of isoforms and related 
functional components [173].  Traditional approaches to quantitative analysis of 
proteomes involve high resolution separation of the proteins (by size and charge) using 
2DE accompanied by identification of the resolved proteins using mass spectrometry 
(MS) [174, 175].  Protein profiles from such analyses can reveal differential protein 
expression between samples which may denote key molecules that are critical to protein 
function. 
In the investigation of the ovarian cancer patient humoral antitumor response, 
this study approaches the use of patient serum autoantibodies in the detection of ovarian 
cancer specific-antigenic protein.  Proteomic analysis allowed for the identification of 
numerous proteins with six of particular interest (GRP78, annexin 2, cathepsin D, alpha-
enolase, HSC70, and PDI) due to their roles in tumor survival and present status as 
potential biomarkers in different cancers.  Here, the identities of these antigenic proteins 
were confirmed by Western and dot blot analyses. One concern in this study was the 
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effects of denaturation on the ability of the antigenic protein to be recognized by our 
commercial antibodies. Hence, we utilized both Western and dot blot analysis to reduce 
the likelihood of “overlooking” the detection of the antigens. As expected, there was 
variability in detection between Western and dot blot analysis of some of the antigenic 
proteins, namely annexin 2, HSC70, and PDI. Dot blot analysis revealed detection of all 
antigens, while Western blot resulted in definitive detection of GRP 78, cathepsin D, and 
alpha-enolase.  
GRP78 (also known as BiP--binding immunoglobulin protein), a member of the 
heat shock protein 70 family, is a molecular chaperone commonly housed in the lumen 
of the endoplasmic reticulum (ER), and its increased expression in the ER is 
instrumental in allowing neoplastic cells to endure the tumor microenvironment [176]. It 
is also expressed on the cell surface in various cancers [177], and its location on the 
surface has been documented to form complexes with ligands important in signal 
transduction [178, 179].  Cell-surface expression of GRP78 in cancer cells has been 
shown to activate pathways that induce cellular survival and proliferation [180, 181], and 
to correlate with the expression of circulating autoantibodies in prostate [182] and 
ovarian [183-185] cancers. Previous studies of circulating ovarian cancer sera 
autoantibodies by the Taylor lab demonstrated recognition of GRP78 and cathepsin D 
(immature proenzyme form and mature form) in ovarian cancer patients [183]. In this 
study, immunoprecipitated antigen probed with commercial antibodies revealed bands 
~75 kDa (corresponding to GRP78), ~48 kDa (corresponding to the intermediate form of 
cathepsin D), and ~47 kDa (corresponding to alpha-enolase).  Cathepsin D is an 
aspartic lysosomal peptidase with a variety of functions including: degradation of 
proteins (intracellular [186], cytoskeletal [187],) activation/degradation of growth factors 
and chemokines [188, 189] , and activation of enzymatic precursors [190].  Synthesis of 
cathepsin D occurs by the rough ER as a “pre-pro” protein which loses its leader 
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sequence (“pre” portion) upon entering the ER lumen.  Processing of the single 
polypeptide immature (pro) form (52 kDa) of cathepsin D occurs through the transport of 
the protein through endosomal compartments and  involves removal of the pro-peptide 
to form the active intermediate isoform (48 kDa).  Eventual formation of the double-
chained mature isoform (34 kDa heavy chain, 14 kDa light chain) takes place in the 
lysosome [191].  The proteolytic activity is seen at the level of the endosome and 
lysosome compartments as a result of the acidic pH of the compartment environment 
[192]. Although present in normal cells, its overexpression has been reported in a 
number of cancers [193]. Functionally, cathepsin D is believed to act on tumor growth 
and metastasis by assisting with stromal remodeling, and affect angiogenesis of tumors 
through the stimulation of endothelial and cancer cells [194].  In the induction of 
apoptosis of human T cells,  cathepsin D appears to be the result of translocation from 
the lysosomes to the cytosol, which triggers Bax (apoptotic-inducing protein) activation 
to induce expression of apoptosis-inducing factor (AIF) [192].  Alpha-enolase is a 
glycolytic enzyme important in the catalysis of 2-phospho-D-glycerate (PGA) to 
phosphoenolpyruvate [195], and is upregulated under stressful conditions, like hypoxia, 
in order to mediate enhanced anaerobic metabolism [196]. Increased autoantibodies 
against alpha-enolase have been recorded in some cases of organ-specific 
autoimmunity [197], and in a number of metastatic cell lines [195]. This study indicates 
strong recognition of immunoprecipitated ovarian cancer antigen by commercial anti-
cathepsin D and alpha-enolase antibodies.  Consistent recognition of human 
recombinant alpha-enolase was seen by serous adenocarcinoma/carcinoma and 
mucinous adenocarcinoma serum antibodies with variation in cathepsin D and GRP78 
recognition between sera types. Additionally, recombinant alpha-enolase was also 
recognized by non-cancer controls.  GRP78 and alpha-enolase were also detected in all 
3 exosome samples, with detection of all 3 isotypes of cathepsin D among the exosome 
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samples. Exosome-associated antibodies also recognized alpha-enolase with faint 
detection of GRP78. Our data suggests that GRP78, cathepsin D, and alpha-enolase 
are tumor-associated antigens that are transported to the released exosome, and elicit a 
humoral response, indicated by the presence of antibodies to these molecules. 
During cellular quiescent phases, the translation of alpha-enolase is virtually 
undetectable but is upregulated in cellular growth phases [198, 199]. In the translation 
process, alpha-enolase can use an alternative start codon which yields the production of 
a 37 kDa isosform, c-myc promoter binding protein (MBP-1), which binds to c-myc P2 
promoter to negatively regulate transcription of c-myc [200], and lacks the enzyme 
activity of enolase [200, 201].  c-myc is an oncogene, commonly overexpressed in the 
majority of human cancers [202], and is responsible for a number of pleiotropic effects at 
the cellular (increases proliferation, metabolic transformation, metastasis) and molecular 
(increases glycolysis, protein biosynthesis, mitochondrial function) levels [203].  
Exogenous expression of MBP-1 has been shown to arrest growth in chronic myeloid 
leukemia cells [204], to suppress proliferation in non-small cell lung cancer [205], and to 
induce death of neuroblastoma cells [206]. The expression of MBP-1 in TDE may play a 
role in the anti- and protumorigenic functions of the TDE.  From the antitumorigenic 
perspective, the transport of MBP-1 in the TDE may be a mechanism for delivery to 
other tumor cells in order to induce c-myc suppression, thereby affecting tumorigenesis. 
In a study conducted by Ghosh et al.( 2002), the transduction of MBP-1 in MCF-7 
(breast carcinoma) cells acted to induce cytochrome c release from the mitochondria, 
which subsequently activated procaspases and cleavage of poly ADP-ribose polymerase 
(PARP) to initiate apoptosis [207].  From the protumorigenic perspective, tumor cells 
may shed MBP-1 in their exosomes as a mechanism to lose the suppressive constraints 
on c-myc so that the tumor cell can continue to proliferate.   
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Annexins are calcium-binding proteins with functions ranging from trafficking of 
vesicles, to apoptosis and regulation of cellular growth [208].  Annexin 2 is a key 
mediator in the plasminogen activator system, in which plasminogen binds to annexin 2 
and is converted to plasmin by tissue plasminogen activator (t-PA) and urokinase 
plasminogen activator (u-PA)  to promote production of products important in clot 
dissolution and wound healing [209].  Located on the surface of endothelial cells and 
various tumor cells [210, 211], annexin 2 can exist as a monomer (~36 kDa) or a 
heterotetramer (~90 kDa) where it complexes with S100A10 (p11), a cell surface 
receptor that regulates the generation of plasmin. Correspondingly, annexin 2 can bind 
to other proteins (e.g. tenascin C, procathepsin B) to facilitate proteolysis leading to 
extracellular matrix degradation instrumental in tumor progression, invasion, and 
metastasis [211].  Because of its functional importance in fibrin production, dysregulation 
of annexin 2 compromises fibrinolysis and may interfere with the proteolytic processes 
needed to ensure tumor dissemination. In disorders characterized by thrombosis (i.e. 
lupus and antiphospholipid syndrome), autoantibodies to annexin 2 were identified, and 
their presence is speculated to be key contributors to pathogenesis [212].  In the context 
of cancer, a study of sera from lung cancer patients displayed IgG1 and IgM 
autoantibodies to annexin 2, which were not seen in the non-cancer controls [213].  In 
our studies, the cellular presence of annexin 2 was validated by dot blot, while both 
isoforms were detected in the patient ascites TDE. In the group of patient TDE samples, 
the presence of annexin 2 was presented as double bands; however, it is not clear as to 
why.  It is known that proteins can undergo post-translational modifications which can 
alter the protein, and previous studies indicate modifications of annexin 2 by 
phosphorylation of tyrosine [214], splice variant formation [215], and partial proteolysis 
[216] .  Investigation of the immunoreactivity of ovarian cancer patient serum antibodies 
confirmed recognition primarily of the heterotetramer form of the antigen.  Annexin 2 is 
31 
 
also integral to cancer progression [217] by influencing migration, proliferation, and 
metastasis. Expression of annexin 2 is varied in different types of cancers [218] with 
increased expression in pancreatic [219] and breast [220] cancers, but variable 
expression in prostate cancer [221, 222].   In prostate cancer, annexin 2 has been 
shown to regulate adhesion and migration to endothelial cells and osteoblasts [223].  
Ovexpression of annexin 2 in multiple myeloma [224] and gastric cancer [225] has been 
shown to enhance proliferation and metastasis, respectively.  Conversely, the 
knockdown of annexin 2 by siRNA demonstrated the reduction in glioma migration [226]  
and multiple myeloma invasion [224].   
Chaperone proteins, HSC70 and PDI were detected by dot blot assay and were 
found to be associated with patient ascites and serum-containing TDE, with additional 
detection of PDI in serum-free TDE. HSC70 is a constitutively expressed cytoplasmic 
protein which binds to new peptides exiting the ribosomes to protect the hydrophobic 
residues from inefficient interactions [227]. Additionally, it can catalyze the disassembly 
of clathrin cages [227] and has been implicated in the regulation of tumorigenesis and 
apoptosis [228]. With the assistance of co-chaperones, HSC70 can be recruited to the 
intracellular membrane [227], but can be released from cells as a result of active 
secretion [229]. Humoral autoimmune reactions against HSC70 have been documented 
in patients with cancer-associated retinopathy (characterized by visual loss and 
impairment) an ocular manifestation of underlying cancer, generally small-cell lung 
carcinoma [230].   These autoantibodies are believed to contribute to the pathogenesis 
of the retinopathy and may not necessarily target the cancer, although other studies 
indicate that sera from cancer-associated retinopathy patients are immunoreactive to 
HSC70 protein from the tumor cell [231, 232].  In establishing malignancy, an 
interrelationship between cathepsin D and HSC70 has been documented.  Studies of a 
cell line transfected with cathepsin D showed that overexpression of cathepsin D 
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resulted in an increase in the malignant phenotype of the transformed cells [233]. 
Subsequent studies of these cells revealed that this overexpression prevented the 
release of HSC70, which led to the malignant phenotype [229]. In our study, the 
expression of cathepsin D was seen in the ovarian cancer cells and all cathepsin D 
isoforms on the exosomes. However, the ovarian patient serum antibodies failed to 
detect cathepsin D in all cases. The antigen expression of cathepsin D, the lack of 
antibodies to cathepsin D, and the reduced HSC70 expression on the cells may indicate 
a “protective” mechanism used by the tumor in order to maintain high cathepsin D 
expression so that HSC70 release can be minimized, and the tumor growth can be 
maintained. Furthermore, the exosome expression of all 3 isoforms may act to “block” 
recognition of antigen on the tumor cell, thereby protecting the tumor from 
immunosurveillance. PDI is a key endoplasmic reticulum chaperone that catalyzes the 
breakage of disulfide bonds within a protein and rearranges them to form the native 
protein [234]. Because accumulation of misfolded proteins in the cell can lead to 
enhanced cellular stress and death [234], upregulation of PDI can act to reduce stress-
associated apoptosis [235].  In the manifestation of an antitumor response to 
spontaneous hepatic carcinoma, PDI autoantibodies have been identified in Long Evans 
Cinnamon rats [236].   At the present, there appears to be minimal information on 
autoantibody production against PDI in humans. However, human immune responses to 
PDI have been documented. Studies of IgA in human tears revealed immunoreactivity to 
PDI in Toxoplasma gondii [237, 238].  Human PDI-family member, ERp5, has been 
shown to promote shedding of MICA from epithelial tumors [239].  MICA is the ligand for 
NK group member 2D (NKG2D) receptor on NK, CD8+T, NKT, and T cells [240] and 
upon ligation, activates cytolysis of the target cell.  Tumor-derived exosomes have been 
shown to express MICA/B, which downregulates NKG2D expression to reduce NKG2D-
mediated killing [241, 242].  In our studies, PDI was strongly expressed in ascites TDE, 
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with less expression in the culture-derived exosomes. Expression of PDI in TDE may 
participate in the facilitation of MICA expression, resulting in interference of innate and 
adaptive immune effector cell function against the tumor, thereby contributing to tumor 
survival. 
TDE do express tumor antigen, and antibodies to those antigens may be 
expressed in the biologic fluids of the tumor patient, as indicated in this study. However, 
those antibodies do not effectively mediate an antitumor response that sufficiently 
eliminates the tumor. We propose that the tumor cell expresses certain antigens in their 
exosomes in order to divert the humoral immune response away from the tumor, thereby 
preventing its effective detection and elimination and allowing for progression. Because 
of the defined presence of autoantibodies in the circulation, and the known association 
of antibodies with exosomes, we further wanted to investigate the antibodies associated 
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Figure 1:  Shared immunoreactivity of rotofor-fractionated cellular lysate with 
antibodies from ovarian tumor patient sera. Serum antibodies of patient  A) UL-224 
(1:250) and B) UL-184 (1:250) were used to detect immunoreactivity with cellular  lysate 
protein  from patient UL-124.  Boxes indicate the shared immunoreactivity between 
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randomly chosen bands. Molecular marker (M) and rotofor fractions (1-20) are indicated 






















     
Figure 2: Validation of identified antigens of interest using commercial antibodies.  
UL-124 cellular antigen was immunoprecipitated by A) Protein G HP SpinTrap columns 
(applied in duplicate) and subjected to dot blot); and B) TrueBlot IP beads and subjected 
to Western blot (representative immunoreactivity shown). Arrows indicate identified 
antigen. Molecular marker (M), immunoprecipitated antigen (IP Ag).  Molecules identified 
in Table 1.
PDI HSC70 GRP78 (BiP) 
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Figure 3:  Validation of ovarian cancer patient serum antibody recognition of antigens of interest using recombinant 
proteins.  Boxes indicate immunoreactivity of recombinant proteins with ovarian cancer patient sera (A-F).  Recombinant 
proteins indicated as: G78 (GRP78), A2 (Annexin 2), CD (Cathepsin D), AE (Alpha-enolase), H70 (HSC 70), PDI (Protein 
disulfide isomerase). Ovals indicate recognition of CD.  Molecular marker indicated by M. Ovarian cancer cell types (A-F) 
indicated as: sa (serous adenocarcinoma), sc (serous carcinoma), ma (mucinous adenocarcinoma). G indicates a mixture of 
commercial antibodies and H, the ncc (non-cancer control). Initial assays showed no reactivity of CD with other sera samples. 
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Figure 4:  Analysis of the association of antigens of interest with in vivo and in vitro-derived exosomes.  Western 
blots of UL-124 ascites-derived (ASC), serum-containing (SC), and serum-free (SF) culture-derived exosomes demonstrating 
immunoreactivity to commercial antibodies corresponding to the antigens of interest (indicated by arrow).   Cathepsin D 
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Figure 5:  Validation of tumor-reactive antigen presence in tumor-derived exosomes using different 
commercial antibodies.  Western blots of TDE patient samples (UL-472, -309, -124, -316,- 224) and a serum 
non-cancer control (NCC) demonstrating immunoreactivity to  A) Annexin 2 and B) Enolase-1 antibodies from 
Cell Signaling Technology. Positive control (+CTRL) cellular lysate, H929 (B cells), indicates molecular 
weights of Annexin 2 ( ~38 kDa) and Enolase-1 (47 kDa). Additional bands detected in the TDE by Annexin 2 
(~50 kDa) and Enolase-1 (~30KDa) suggest the presence of isoforms of these molecules. 
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ISOLATION OF TDE-ASSOCIATED IMMUNOGLOBULIN REVEALS PRESENCE OF 




Malignant cells are often a consequence of aberrant gene expression which 
influences  production of abnormal cellular proteins presented as new or altered antigen 
[243]. Often, these antigens are shed from the malignant cells [244, 245], leading to their 
enhanced expression in the body fluids. Although shedding has been identified as an 
immunosuppressive mechanism used by tumors to escape antitumor immunity [246], 
studies indicate that shed antigen can be detected by the immune system and elicit 
cellular and humoral antitumor responses in different cancers [86, 247-249]. These 
antitumor responses are manifested by increased frequency of antigen-specific CD8+ 
and CD4+ T cells [247] and tumor-reactive antibodies [143, 152, 158] in the peripheral 
circulation. In experimental animal models the appearance of tumor-reactive antibodies 
is evident promptly after induction of the tumor and prior to the detection of palpable 
tumors or tumor antigen [143, 152, 158].   In a number of malignancies, the distinct 
presence of circulating autoantibodies has been documented  [250], and unlike other 
circulating components, they have long half-lives and are stable [159].  Collectively, the 
early emergence, availability, and stable presence of tumor-reactive antibodies establish 
a promising platform for investigation of the humoral antitumor response. 
 Expression of this humoral antitumor response is reflected through increased 
levels of IgG in the blood and sera [155, 156], which is characteristically indicative of 




serum of healthy adults [251], and is distributed as four subtypes (IgG1, IgG2, IgG3, and 
IgG4) named in accordance with their normal abundance in the serum [252].  The 
relative serum concentration of IgG is dependent upon the number of plasma cells 
producing that particular subtype and their metabolic rates in the 
intravascular/extravascular space [251].  However, during the humoral immune 
response, the distribution of the subclasses is adjusted, resulting in an altered IgG profile 
and consequently, modification in effector activity. Immunoglobulin levels in the serum 
can provide critical information on the status of humoral immunity [253], and may be 
instrumental in defining humoral immunodeficiencies [254] or other disorders or 
malignancies [255].  In patients with primary Sjorgen’s syndrome (chronic autoimmune 
disorder targeting moisture-producing glands), analysis of the sera revealed increases in 
IgG1 and IgG3, substantiating the pathogenicity of the disease [256]. Studies of the 
isotype patterns of multiple myeloma sera indicated variation among subclasses and 
heterogeneity in hypogammaglobulinemia patterns [257]. The correlation of 
immunoglobulin effector activity with IgG subclass expression suggests the importance 
of investigating subclass distribution because of its potential for insight into the 
ineffective immune responses seen in other conditions or disorders. 
Tumor-reactive IgG is elevated in the sera of ovarian cancer patients [159], and 
in experimental animal models,  is expressed in the circulation before palpable tumors or 
circulating tumor antigens [258].  IgG may exist as free immunoglobulin or may be 
associated with tumor-derived membrane fragments [126] which include vesicular 
structures ranging from high molecular weight complexes to microvesicles and 
exosomes.  Originally demonstrated in the peripheral circulation of patients with ovarian 
cancer [121, 259, 260], tumor-derived exosomes (TDE) express a membrane molecular 
representation of the tumor cell and enhanced expression of tumor antigen [115, 261].  




displayed high levels of IgG bound to their surface [115, 121, 126], suggesting a humoral 
immune response to surface antigenic protein. The antibody response to antigen 
expressed on the exosome indicates that these antibodies are specific and display high 
affinity for the tumor antigen. Isolation of these antibodies could provide information on 
the immunoreactivity, structure, subclass, and effector function of the tumor-reactive 
IgG.  Furthermore, exploiting the use of TDE as the antibody source for detection of 
tumor antigen may be more informative than free antibody in sera because the antibody 
is bound to the antigen, and the antigen has been “selected” in the formation of the 
exosome. Therefore, we hypothesize that the ovarian tumor humoral response 
associated with TDE can recognize and identify ovarian tumor antigen, which may be a 
mechanism used by the tumor cell to discourage recognition and stimulation of an 
antitumor response. 
 
Materials and Methods 
Patient Ascites 
Ascites used in this study was derived from ovarian tumor patients diagnosed 
with Stage III (T3c) serous carcinoma (UL-124, TB-0836, ML-457), serous/endometrioid 
mixed carcinoma (UL-472), and presentation of a pelvic mass (UL-309).  Control serum 
was derived from age-matched women with no evidence of ovarian disease.   
Isolation of Circulating Ovarian Tumor-derived Exosomes (TDE) 
Exosomes were isolated from ovarian tumor-patient ascites and control serum by 
a two-step procedure developed in our laboratory [126]. Initially, the biological fluids 
were centrifuged at 400 x g for 10 minutes (to remove whole cells). 10-20 mL of cell-free 
ascites was concentrated by ultrafiltration using an Amicon Stirred Cell (Model 8200) 
and a membrane with a molecular weight cut off of 500,000 Daltons (Millipore) to 




was applied to a 2% agarose (ABT) chromatography column (1.5 x 20 cm) equilibrated 
with ddH2O or 1X TBS.  1 mL-fractions were collected and the absorbance (280 nm) of 
the elution was monitored. Fractions containing material greater than 50 million Daltons 
were obtained, ultrafiltrated, and the quantity of protein assayed by the Bradford method 
(Bio Rad).  
Nanoparticle Tracking Analysis (NTA) 
Exosome samples were diluted 1:10 with 1X  PBS and NTA measurements (at 
room temperature) were performed using a NanoSight LM10 (Nanosight Ltd). NTA 2.3.5 
software was used for capturing and analyzing the data.  
Isolation of Bound and Unbound Exosome Populations 
Exosomes were isolated from UL-124, UL-472, UL-309, TB-0836, ML-457 patient 
ascites and normal control serum using the aforementioned two-step procedure. 
Exosome fractions were pooled and ultrafiltrated 10-fold, and the concentrated sample 
prepped for use with the HiTrap Protein G HP column (GE Healthcare). In short, 1 mL of 
binding buffer (20 mM sodium phosphate, pH 7.0) was combined with the exosome 
sample prior to application onto the column. The column was washed with 10 column 
volumes of binding buffer at 1 mL/min, and the sample was applied to the column under 
closed recirculation for 1 hr. Post recirculation, the system was opened and the unbound 
material (U), fraction containing exosomes without associated IgG, was collected. The 
column was washed with 10 column volumes of 1X PBS, and the exosome-bound IgG 
fraction (B) was eluted isocratically using IgG Elution buffer, pH 2.8 (Pierce). Eluted 
fractions were neutralized with 1M Tris-HCl (pH 9) and unbound and bound fractions 
were concentrated by ultrafiltration. Protein concentration of bound and unbound protein 






Western Blot Analyses of Exosome Protein Expression 
Western blotting was performed to analyze the presence of common exosome 
markers (CD63, CD81).  40 g of ascites bound and unbound exosome protein (TB-
0836, ML-457) was loaded onto a 10% SDS-PAGE gel, transferred  to nitrocellulose 
membrane (Bio Rad) on ice for 1h at 98 V, blocked with 5% blotting grade blocking 
grade nonfat dry milk (Bio Rad) and probed with commercial antibodies (1:1000, Santa 
Cruz Biotechnology) corresponding to common exosome markers. 
Isolation and Verification of Exosome-Associated IgG 
In preliminary experiments, 1 mL of patient UL-124, UL-472, and UL-309 ascites-
derived exosomes were subjected to different methods in order to ascertain the optimal 
method for isolation of IgG. Based upon the results, we proceeded with the vivaspin 
method of isolation. Here, the 1-mL exosome sample was combined with 50 L 
increments of IgG elution buffer until a pH of ~3.0 was obtained. Samples were 
incubated with end-over-end rotation on the Labquake rotisserie shaker (Barnstead 
Thermolyne)  for 30 minutes at room temperature and then added to a pre-rinsed (1X 
PBS) Vivaspin 2 centrifugal concentrator with a membrane MWCO of 1 x 106 (Sartorius 
Stedim Biotech). IgG was eluted from the exosomes by centrifugation (4000 x g, 20 
min.), collected from the filtrate tube, and neutralized using 1M Tris-HCl, pH 9.0. IgG 
protein was quantitated by the Bradford method. To verify IgG isolation from TDE, 0.5-1 
g isolated IgG was loaded onto a NuPAGE  4-12% Bis-Tris gel (Novex) along with 0.1 
g human IgG subclass control serum (1:20, The Binding Site), electrophoretically 
separated using MOPS SDS Running Buffer (1X, Novex) under reducing conditions, and 
transferred/blocked according to aforementioned methods.  Efficient IgG isolation was 
analyzed by immunoreactivity of peroxidase-conjugated anti-human polyvalent 




Analysis of Immunoreactivity and Subclasses of Isolated Exosome-associated IgG 
Post verification of IgG isolation, 0.5g of GRP78, annexin 2, cathepsin D, 
protein disulfide isomerase (PDI; all from ProSpec Bio), alpha-enolase (American 
Research Products), and HSC70 (Enzo Life Sciences) human recombinant proteins 
were combined with 4X  LDS Nonreducing Buffer (ThermoScientific), loaded onto a Mini 
PROTEAN TGX 4-15% gel and electrophoretically separated.  Immunoreactivity of the 
isolated exosome-associated IgG was analyzed by Western blot using the isolated IgG 
at 1:50. For the subclass analysis: 3 g of isolated IgG protein was loaded on to a 
Criterion TGX 4-20% gel, electrophoretically separated, transferred using Trans Blot 
Turbo Transfer System (Bio Rad) with TransBlot Transfer Pack Midi Format –
Nitrocellulose (Bio Rad), blocked with 5% nonfat milk, and probed with monoclonal 
mouse anti-human IgG1, IgG3, IgG4 (1:10,000, Sigma) and IgG2 (1:20,000, Sigma). 
 
Results 
 Acquisition of TDE Populations 
In the isolation of exosomes from patient biological fluids it is expected that a 
subset of the exosome population is derived from the tumor and the remaining may be 
derived from normal cells. To investigate the differences between these exosome 
populations, exosomes were first isolated from ovarian tumor-patient ascites and normal 
serum. Using the two step isolation procedure, samples were concentrated by 
ultrafiltration and applied to 2% agarose columns, monitoring elution at 280 nm. The 
fractions containing the exosome populations were acquired, combined with sodium 
phosphate (to enhance the affinity of any IgG associated with the exosomes to the 
protein G) and further separated using a HiTrap Protein G HP column.  HiTrap Protein G 
HP columns specifically recognize all subclasses of IgG.  In the application of the 




that express tumor antigen) bind to the column, while exosomes that lack bound IgG 
(those that express normal antigen) “flow through”. The “flow through” represents the 
unbound fraction of exosomes. Using low pH buffers to reduce affinity between protein G 
and IgG, bound exosomes were eluted, collected, and neutralized with Tris buffer (pH 9) 
to maintain the stability of the eluted IgG after being exposed to acidic conditions (Fig. 
6). 
Verification of Exosome Acquisition 
Protein concentrations of eluted bound and unbound exosome fractions were 
obtained, analyzed by SDS-PAGE, and subjected to Western blot.  Since CD63 and 
CD81 have been demonstrated as markers of exosomes, their presence on bound and 
unbound populations were analyzed.  CD63 and CD81 were present in both bound and 
unbound populations with slight variation in intensity between patient samples (Fig. 7A). 
Additionally, the sizes of the isolated nanoparticles were verified using Nanoparticle 
Tracking Analysis (NTA) (Fig. 7B), with bound fractions in the 30-100 nm range and 
unbound fractions in the higher ranges (primarily >100 nm), thereby confirming the 
isolation of exosomes. 
Association of IgG with TDE Populations 
 To establish the association of immunoglobulin with TDE, fractions collected by 
our two-step method were prepared as aforementioned, applied to a HiTrap Prot G HP 
column, and eluted.  Since exosomes from non-malignant cells can be present in 
malignant effusions, the association of IgG with bound and unbound populations was 
investigated to distinguish between exosomes of malignant and non-malignant origin.  
Patient bound exosome fractions revealed bands corresponding to the IgG heavy (50 
kDa) and light chains (25 kDa), while little to no immunoreactivity was seen in the patient 




Isolated IgG displays Immunoreactivity to Cellular Antigen 
 Because IgG association to TDE suggests the occurrence of an immune 
response, further analysis of the exosome-associated IgG should provide insight on the 
specificity and affinity of the TDE for tumor antigen. To isolate the exosome-associated 
IgG, exosomes were subjected to chemical treatment to separate the IgG from the 
exosome surface and concentrated using nanomembrane centrifugation to separate the 
extracted IgG from the exosome. The protein concentration of the isolated IgG was 
acquired and its presence verified by Western blot which identified IgG heavy and light 
chains (Fig. 8b). The affinity and specificity of the isolated IgG was evaluated by 
analyzing its immunoreactivity to the six immunogenic proteins identified via mass 
spectrometry. Immunoreactivity was seen with annexin 2 (higher and lower molecular 
weight forms), alpha-enolase, and HSC70, with faint recognition of GRP78 (Fig. 8C). 
Subclass Characterization of Exosome-Isolated IgG 
 Since human IgG is comprised of different subclasses, it was of interest to 
analyze the isolated IgG to see if particular subclasses are associated with TDE (Fig.9). 
Analysis of total IgG revealed heavy and light chains in the commercial control and 
patient samples, with no IgG seen in the non-cancer control. Although multiple bands 
were seen in the cancer patient samples in all subclasses, there were variations of 
intensity between the subclasses. Banding patterns with anti-IgG1 and IgG2 were more 
intense and similar to anti-total IgG for patient sample 472, 124 (double bands), and 309, 










Tumor progression and metastasis is influenced by the tumor microenvironment 
[161] which facilitates the expression and release of a number of biological constituents 
[128], including enhanced release of microvesicles/exosomes into the circulation [115, 
116]. The enhancement of circulating TDE has been implicated not only as a 
communicative mechanism with the microenvironment in order to expedite effector 
functions in the target cell [106] and mediate tumor progression [113, 163, 262-264], but 
also as a diagnostic mechanism to be utilized as an approach in cancer detection [265, 
266].  Proteomic analysis of effusion-derived exosomes has demonstrated the presence 
of both common and unique proteins, which has expanded the present knowledge of 
exosome composition. In addition to the expression of common surface antigen, TDE 
display immunogenic  antigen specific to the tumor from which it is derived such as 
MelanA/Mart 1 in melanoma [113] and carcinoembryonic antigen (CEA) in colon 
carcinoma [111]. In the context of ovarian cancer, several tumor cellular antigens (e.g.  
Her2/neu, MUC-1) [267-270], ovarian antigen-3 (OA-3) [271], and cancer testis antigen  
(NY-ESO-1) [272]) have been identified . However, the association of these antigens 
with ovarian cancer exosomes is somewhat ambiguous. In this study, proteomic 
analyses of circulating antibody immunoreactivity to ovarian cancer lysates led to the 
identification of six proteins (GRP78, annexin 2, cathepsin D, alpha-enolase, HSC70, 
PDI) and further investigation revealed the association of these same proteins with 
ovarian tumor exosomes.  
The association of immunogenic antigen to ovarian cancer exosomes elicits an 
immune response resulting in the production of immunoreactive antibodies which bind to 
exosome-associated antigen. The antibody-associated exosomes are what we are 
defining as “bound exosomes.” To isolate bound exosomes, exosome fractions were 




cell surface FcRIII which binds the Fc portion of IgG.  The bound exosomes are eluted 
from the column using low pH buffers. As the exosome sample flows over the column, 
those exosomes that are associated with IgG are trapped onto the column, allowing 
exosomes without IgG to flow through. The flow-through fraction is what we define as 
“unbound exosomes.” In previous studies (not shown here), analysis of the association 
of the proteomics-identified proteins with bound and unbound exosome fractions 
confirmed the presence of each of the six proteins, with suggested enrichment in the 
bound fractions.  Since bound exosomes are likely derived from the tumor cells, it is 
expected that the identified proteins from the tumor would be enriched in its exosome 
derivative.  
In order to gain a deeper understanding of the humoral response to ovarian 
tumor antigen, the antibodies associated with the bound exosomes were isolated using 
centrifugal concentration of bound exosome fractions in low pH buffers. Eluted antibody 
was verified and then used to investigate immunoreactivity to recombinant antigens 
corresponding to the proteomics-identified proteins.  Although recognition of only 4 
(annexin 2, alpha-enolase, HSC70 and faint recognition of GRP78) of the six proteins 
was seen, it is important to remember that immunogenic proteins typically display 
modifications which are instrumental in their immunogenicity.   Moreover, these 
modifications may or may not be present in the recombinant protein, which would affect 
recognition of the epitope by its corresponding antibody. 
To acquire further insight into the exosome humoral response, we verified the 
presence of exosome-associated IgG and analyzed the subclass distribution of the 
isolated exosome-associated IgG.  IgG is a large (150 kDa), bilaterally symmetric 
glycoprotein made of two heavy (50 kDa) and two light (25 kDa) polypeptide chains 
associated by inter- and intra-chain disulfide bonds [273].  It is composed of 3 




antigen, and a single Fc (“fragment crystallizable”) region which interacts with effector 
cells and molecules [157].  In humans, IgG is further categorized into 4 subclasses: 
IgG1, IgG2, IgG3, and IgG4. Although the general structure of the subclasses is the 
same, there is some variation seen in the flexibility of the hinge region and the positional 
attachment of the light chain to the heavy chain [251]).  These structural variations in the 
hinge region and in the Fc region are important in establishing the biological functions of 
the subclasses [274].  The key biologic functions of the IgG subclasses are complement 
fixation and opsonization.  In the fixing of complement, the Fc portion of IgG (bound to 
pathogenic surfaces) is bound by complement protein 1 (C1). This triggers a cascade of 
reactions, eventually leading to the formation of a membrane-attack complex (MAC) 
which lyses the target [275, 276].  Of the IgG subclasses, IgG1 and IgG3 are the most 
efficient at fixing complement, followed by weak fixation by IgG2 and the absent fixation 
of IgG4 [273].  The process of opsonization involves the coating of antibodies onto the 
surface of a pathogen or foreign substance in order to promote Fc receptor-mediated 
phagocytosis [157] .  The Fc regions of IgG (particularly IgG1 and IgG3 and to a lesser 
degree, IgG2) are recognized by the Fc-gamma receptor of phagocytes, triggering 
phagocytosis and eventual killing of the target [277].   
Here, isolated TDE IgG was subjected to SDS-PAGE and Western blotted with 
IgG subclass antibodies.  Immunoreactivity to all antibodies was evident with the 
revelation of IgG heavy (50 kDa) and light (25 kDa) chains in all of the cancer patient 
samples.  However, with the IgG1 and IgG2 antibodies, the heavy chain bands were 
more distinct, suggesting that IgG1 and IgG2 are the predominant subclasses 
associated with TDE.  Additionally, doublet bands appeared in the heavy chain migration 
of patient sample UL-124, suggesting heterogeneity of that protein [278] or a potential 
post-translational modification.  Expression of IgG1 and IgG2 as predominant subtypes 




response and promote immunomodulation.  The expression of tumor antigen on the TDE 
and ovarian tumor cell stimulates a humoral antitumor response in which alI subclasses 
would bind to the tumor antigens, but all may potentially be unable to actively participate 
in the antitumor response. Research indicates that some IgG subclasses are functionally 
more protective. IgG1 and IgG3 are known as cytophilic antibodies (have a strong 
affinity for FcR) and are able to mediate cell destruction by complement-dependent 
cytotoxicity (CDC) and antibody-dependent cell mediated-cytotoxicity (ADCC). In clinical 
studies of IgG isotype distribution in the sera of individuals protected from and affected 
by Plasmodium falciparum (causative agent of malaria), higher levels of IgG1 and IgG3 
were found in protected adults, while IgG2 and IgG4 levels predominated in 
nonprotected individuals [279]. Because of their ability to bind and recognize the same 
epitopes, it is hypothesized that the IgG2 and IgG4 are binding in order to block the 
protective activity of the other isotypes [280]. In vitro analyses of Plasmodium falciparum 
in the presence of blood monocytes inhibited phagocytosis and opsonization as a result 
of IgG2 and IgG4 presence, and allowed continued growth of the microorganism [281, 
282]. In our analysis, we speculate that the predominant presence of IgG1 (to invoke an 
immune response against the tumor) and IgG2 (to block the strength of the immune 
response against the tumor) on the TDE surface may be humoral contributors to the pro- 
vs. anti-tumor dichotomy. Additionally, we surmise that the ovarian tumor utilizes its 
release of TDE as a “decoy” to capture opsonizing antibodies in the attempt to promote 
its own survival.  
In summary, analyses of the ovarian TDE humoral response revealed the 
presence of all IgG isotypes and their ability to recognize ovarian tumor antigen, thereby 
suggesting the mobilization of an anti-tumor response. However, the prevalence of non-
cytophilic antibodies (i.e. IgG2) indicates a potential defense mechanism exploited by 




TDE “absorption” of cytophilic antibodies. Collectively, these mechanisms may be 
instrumental in promoting survival of the ovarian tumor and protecting it from the 








capture by Protein G, 
exosomes without IgG 
“flow through” 
+ IgG elution buffer (pH~ 2.9) 
 “flow through” exosomes 
(unbound fraction) 
 eluted IgG-bearing exosomes 
(bound fraction) 
Figure 6:  Separation of IgG –bound vs. unbound exosomes.  Concentrated 
exosome fractions are recirculated onto a HiTrap Protein G HP Column to allow 
exosomes that bear IgG to bind to the column. Post recirculation, the exosome 
fractions without IgG are allowed to “flow through” and are collected. These fractions 
represent the “unbound exosomes.” To elute the IgG-bearing exosomes from the 
column, IgG elution buffer (pH 2.9) is applied. These fractions, which represent the 
“bound exosomes,” are neutralized with 1M Tris (pH 9). 
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Figure 7:  Verification of exosome acquisition utilizing common exosome 
markers and nanoparticle tracking analysis (NTA).  Bound and unbound 
exosome fractions of patient TB-0836 and ML-457 ascites exosomes were acquired 
and verified by Western blot for  A) CD63 and CD81, and the nanoparticle size 
distribution in the fractions determined by B) nanoparticle tracking analysis.  TB-B 
(bound exosomes from patient TB-0836), TB-U (unbound exosomes from patient TB-
0836), ML-B (bound exosomes from patient ML-457), ML-U (unbound exosomes 
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Figure 8: Verification and isolation of patient-bound ascites exosome IgG and 
its immunoreactivity to mass-spectrometry identified antigen. A) Western blot of 
patient UL-472, UL-124, UL-309, and non-cancer control (NCC) bound (B) and 
unbound (U) exosome fractions reveal association of IgG with exosomes. B) Western 
blot of isolated IgG (IS) from patient UL-124 ascites bound exosomes (0.5 g, 1 g) 
along with commercial IgG control (CC; 0.1 g).  C) Western blot of immunoreactive 
isolated patient IgG to recombinant proteins corresponding to mass spectrometry 
antigens of interest. Recombinant protein abbreviations indicated in Figure 3.  Heavy 










Figure 9:  Subclass characterization of isolated tumor-derived exosome-IgG.  Western blot of isolated patient ascites 
exosome- IgG probed with  a) anti-human IgGAM (1:5000), B) anti-human IgG1, C) anti-human IgG2, D) anti-human IgG3, E) 
anti-human IgG4.  Anti-human IgG2 (1:15,000), all other antibodies (1:10,000).  Molecular marker (M), commercial IgG control 
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OVARIAN TDE MEDIATION OF THE HUMORAL RESPONSE BY  
INDUCTION OF B CELL APOPTOSIS 
 
B Cell Biology and Responses in the Normal and Tumor Microenvironment 
 As one of the lymphocyte derivatives of the common lymphoid precursor, B cells 
begin their earliest development in the fetal liver and subsequent post-birth development 
in the hematopoietic bone marrow via adhesive and chemical interactions with bone 
marrow stromal cells.  Within the bone marrow, early B cells differentiate and functionally 
rearrange their immunoglobulin gene segments with the assistance of recombination 
activating genes (RAG-1/RAG-2), to produce a heavy chain and or light chains, 
resulting in production of immature B cells that express the surface B cell receptor 
(BCR), IgM [157]. The immature B cells leave the bone marrow and migrate into the 
periphery, continuing their development through transitional stages where they undergo 
negative selection processes in order to generate B cells that are capable of survival and 
progression towards maturity [157]. As a consequence of transitional differentiation and 
BCR signaling strength [283], immature B cells form mature subpopulations, namely  
marginal zone B cells which assist in ensuring a rapid antibody response during the 
lapse between innate and T cell dependent adaptive antibody responses [284] and  
follicular B cells which may recirculate and enter/exit the follicular microenvironment of 
secondary lymphoid organs in search of antigen [285].  In response to chemokine cues, 




proliferation to create germinal centers (specific microenvironments of dividing cells 
[286] in which antibody affinity maturation takes place [287]). In response to the rapid 
proliferation, anatomically and functionally distinct polar regions are created i.e. the dark 
zone (contains the rapidly dividing B cells called centroblasts) and the light  
zone (contains fewer B cells called centrocytes, but a number of follicular dendritic cells) 
[288].  The interactions of these B cells with helper T cells (within the dark zone) and 
follicular dendritic cells (within the light zone) are critical in initiating class switch 
recombination (CSR) and somatic hypermutation (SHM), two processes that target the 
rearrangement and mutation of immunoglobulin genes in order to produce the high-
affinity immunoglobulin needed to facilitate an adequate humoral response [289].    
 In the context of pathogenesis, the behavior and function of B cells is not as well 
documented or characterized as that of other immune cells.  In autoimmune or organ-
specific disorders, the formation of germinal centers is common [290],  resulting from the 
pro- inflammatory conditions/cytokines which promote germinal center organization [291, 
292].  As a result, B cell production is generally abundant. However, in some 
autoimmune conditions, the presence of these B cells suggests more harm than benefit 
due to their potent antigen-presenting function to their cognate helper T cells [293] and 
their production of autoantibodies [294].  In the tumor microenvironment, B cells have 
been proposed contribute to immunomodulation by:  1) altering cytokine and/or 
chemokine levels in the circulation [120] and  2) producing antibodies to human tumor-
associated antigen which in a study of bladder cancer, correlated with decreased patient 
prognosis and survival [295].  Additionally, the elevated levels of antitumor antibodies 
typically result in the formation of immune complexes which accumulate [296] and 
further contribute to an unfavorable prognosis [297-299].  Alternative contributions to 
immunomodulation in the tumor microenvironment are demonstrated through the release 




cancer cell cultures [300]  and malignant effusions [113] including mesothelioma patient 
pleural fluid [112] and peritoneal ascites [301].  Evidence suggests that in a number of 
cancers, tumor-derived exosomes (TDE) act as an “immunological accomplice” to 
promote the progression of their parent cells.  One of the mechanisms used by 
exosomes is the induction of apoptosis in effector immune cells, particularly T cells.  A 
study of melanoma-derived exosomes revealed the induction of T-cell apoptosis via 
expression of FasL [302], while human colorectal microvesicles were found to induce 
apoptosis of CD8+T cells through expression of both FasL and  tumor necrosis factor-
related apoptosis inducing ligand (TRAIL) [111]. In ovarian cancer patients, T cells have 
been shown to display enhanced apoptosis and diminished expression of CD3-zeta 
[303, 304].  To address these findings, previous studies by the Taylor lab indicated that 
ovarian cancer exosomes suppress both CD3-zeta and JAK-3 and suggested that the 
exosomes could be the link between the reduced expression of CD3-zeta and apoptosis 
of T cells [305]. Taking these immunomodulatory characteristics into account, this 
current investigation explores the relationship between ovarian tumor-derived exosomes 
(TDE) and the ovarian cancer humoral antitumor response by evaluating the effects of 
these exosomes on B cells.  Our findings indicate that ovarian cancer TDE induce 
apoptosis in B cells in a dose-dependent manner and enhance the expression of 
immunomodulatory molecules which have been documented to mediate apoptosis and 
assist in immune escape. Based upon these findings, we propose that ovarian cancer 
TDE can induce apoptosis in B cells as a mechanism to divert the ovarian cancer 








Materials and Methods 
Cell Cultures 
Ramos B cell line (human Burkitt’s lymphoma, ATCC) was maintained in  
Hyclone RPMI 1640 medium (ThermoScientific) supplemented with 10% fetal bovine 
serum (FBS, Biowest), and 100 units/mL gentamicin 10 (Atlanta Biologicals) in a 
humidified incubator at 37C with 5% CO2. For cocultures, cells were transferred into 
culture medium with 10% exosome-depleted FBS (Exo-FBS, SBI).  As previously 
mentioned (chapter 3), primary ovarian tumor cell cultures were established from UL-124 
ascites and grown in Hyclone RPMI 1640 medium (ThermoScientific) supplemented with 
2mM L-glutamine, 10% fetal bovine serum (FBS, Biowest), 1mM sodium pyruvate 
(CellGro, Mediatech),  0.1 mM nonessential amino acids (CellGro, Mediatech), and 100 
units/mL penicillin-streptomycin (Gibco, Invitrogen) in a humidified incubator at 37C with 
5% CO2. After assurance of confluence, cells were transferred into Ultraculture General 
Purpose Serum-Free Media without L-glutamine, but supplemented with the same 
amount of sodium pyruvate, non-essential amino acids, and penicillin-streptomycin in 
order to ensure that the exosomes later collected would be derived from the tumor cells 
and not the FBS. Later, exosome-free FBS (Exo-FBS, SBI) was purchased and 10% 
was added to this media. 
Isolation and Preparation of Culture Supernatant Exosomes 
Supernatant from the UL-124 ovarian cancer cell culture was collected and 
centrifuged at 400 x g for 10 minutes to pellet any cells present in the supernatant. The 
cell-free culture supernatant was ultrafiltrated (under sterile conditions) using an Amicon 
Stirred Cell (Model 8200) and a membrane with a molecular weight cut off of 500,000 
Daltons (Millipore) to concentrate high molecular weight molecules. 1 mL-aliquots of the 




20 cm) equilibrated with sterile ddH2O.  1 mL-fractions were collected and the 
absorbance (280 nm) of the elution was monitored. Fractions containing material greater 
than 50 million Daltons (exosome fractions) were obtained, ultrafiltrated, and the quantity 
of exosome protein assayed by the Bradford method (Bio Rad). A chromogenic LAL 
assay (GenScript) was performed to assess endotoxin levels in the exosome 
preparations. Preparations with detectable levels above the acceptable range were 
subjected to endotoxin removal (MoBio) and endotoxin content reassessed. All 
endotoxin content levels were < 0.2 EU/mL. Exosome protein concentration was 
reacquired by BCA protein assay (ThermoScientific Pierce) and exosome preparations 
were dispensed into 100 g/mL aliquots in preparation for cocultures. 
Coculture of B cells with Ovarian TDE 
 Ramos cells (1 x106) were cocultured alone or with UL-124 culture supernatant 
exosomes at varying concentrations (10, 20, 50, and 100 g/mL) for 3, 6, 18, and 24h.  
Cells were pelleted (2000 rpm, 5 min) and supernatant collected for human cytokine 
array analysis. Cells were washed with sterile 1X  DPBS (CellGro, Mediatech) and lysed 
on ice using lysis buffer (125 mM Tris (pH 6.8), 2% SDS, 20% glycerol, 100 M PMSF, 
protease inhibitor cocktail and phosphatase inhibitor (100X)). Lysed cells were 
centrifuged at 13,000 rpm for 10 minutes to pellet debris. Lysate was stored at -20°C 
until use.  
Trypan Blue Assay 
Post culture, 20 L of the culture suspension was mixed with an equal amount of 
0.4% trypan blue (Sigma) and live and dead cells counted using the Neubauer 
hemocytometer (Reichert).  Each sample was assayed three times in triplicate. 
Percentage of dead cells (% dead) were calculated and expressed as mean ± standard 




(version 4.03) graphing and statistical software. A p-value <0.05 was considered 
statistically significant. 
Analysis of B Cell Apoptosis 
 Apoptosis was analyzed by agarose gel electrophoresis and Western blot using 
antibodies to common apoptotic markers. Agarose gel analysis was performed as 
indicated by Kasibhatla et al. [306], with some modifications. In short, 2.5 x105 cells were 
cocultured with UL-124 exosomes as previously mentioned. Cells were collected, 
supernatant removed, and cells lysed using TES (Tris, EDTA, SDS) buffer with added 
RNase cocktail (Ambion) and incubated at 37°C for 1 h. Proteinase K (Qiagen) was 
added and cells incubated at 50°C for 1 h, followed by a 5 minute incubation at 65°C. 
Samples were mixed with 5X Loading Dye (Qiagen) and loaded onto a 1.2% agarose 
FlashGel DNA Cassette (12 +1, Lonza) with the Flash Gel DNA marker (100-4000 bp, 
Lonza).  Marker and samples were electrophoresed on the FlashGel system (Lonza) at 
237 V. Images were captured using the FlashGel camera and capture software.  For 
Western blot analysis: 10 g coculture cell protein was loaded onto a 4-20% Criterion 
TGX Precast Gel (Bio Rad), electrophoresed and transferred using Trans Blot Turbo 
Transfer System and transfer pack (0.2 m nitrocellulose, Bio Rad).  Membranes were 
blocked with 5% nonfat dry milk and probed with PARP, caspase-3 (Cell 
Signaling,1:1000), and -actin (Jackson ImmunoResearch, 1:5000) commercial 
antibodies. To analyze potential mechanisms of apoptosis by TDE, in vivo-derived (UL-
472, 309, 316, 224) and in vitro-derived (UL-124, UL-OY) exosomes were isolated (as 
mentioned previously) and solubilized in reducing buffer (62.5 mM Tris-HCl pH 6.8, 25% 
glycerol, 2% SDS, 0.01% bromophenol blue, 5% -mercaptoethanol) and boiled for 5 
minutes. 20 g of in vivo exosome protein and 45-60 g of in vitro exosome protein was 




respectively, and transferred at 98 V (on ice) for 1h. Membranes were blocked and 
probed with anti-CD40L (for in vivo sample) and anti-FasL ( for in vitro sample), both 
1:1000 (Santa Cruz Biotechnology).   
Analysis of Coculture Supernatant using an Antibody Array 
 To investigate the effects of TDE on B cell cytokine and chemokine profiles, the 
relative levels of coculture proteins including cytokines and chemokines in the 
supernatant was analyzed by ProteomeProfilerTM Human Cytokine Array Panel A (R&D 
Systems) according to the manufacturer’s instructions. In short, coculture supernatant 
was incubated with array assay buffer and detection antibody, then added to blocked 
array membranes to incubate overnight at 4°C. Membranes were washed with assay 
wash buffer (1X) and incubated at room temperature for 30 minutes with horseradish 
peroxidase conjugated-streptavidin (1:2000). Membranes were washed and revealed 
using the array chemiluminescent peroxidase substrate reagent 1 and 2 (1:1).  Results 
were scanned and quantitated using UN-Scan-IT gel and graph digitizing software 
version 6.1 (Silk Scientific). Positive controls at three spots were used to normalize the 
results and to orient the membranes. For each spot, the net pixel value was determined 
by subtracting the background pixel value from the raw pixel values. The average of the 
reference spots (positive controls) was obtained and multiplied by the net pixel value to 
normalize the values. To calculate the fold change in cytokine levels between samples, 
the normalized treated value was divided by the normalized control value corresponding 
to that particular spot. Differences in cytokine levels ± 2 fold  (compared to 
corresponding controls) were considered significant. 
Results 
Coculture of UL-124 Patient-Derived Exosomes with Ramos B cells 
 Since this study investigates the role that TDE play in mediating the humoral 




see if exosome dosage and length of exposure modified the outcomes. To do so, Ramos 
cells were cocultured with exosomes at different doses (10, 20, 50, and 100 g/mL) for 
3, 6, 18, and 24h. Post coculture, cells were collected and a fraction saved for 
hemocytometer counts using trypan blue to ascertain viability. Counts revealed 
decreases in cell viability with increasing dosages of exosomes and longer lengths of 
exposure (Fig. 10).  To distinguish whether these exosome-mediated mechanisms of cell 
death were a result of apoptosis or necrosis, Western blot with several apoptotic 
markers was utilized along with analysis of DNA fragmentation using agarose gels. 
Presence of uncleaved PARP was seen at all time points with enhanced presence at 6h 
followed by subsequent increases at the latter time points (Fig. 11). Cleaved PARP  
(indicative of apoptosis) is evident at 6h with enhanced presence in the latter time points, 
particularly in the samples cocultured with the highest dosage of exosomes (T6, T18, 
T24--Fig. 11A).  Additionally, the greatest amount of cleaved PARP is seen at 18h, 
which suggests that this time point may be critical in the apoptotic response for the B 
cell. Furthermore, the seemingly absent  -actin at 18 and 24h at the highest dosage 
suggests death of these cells, with death resulting from apoptosis since cleaved PARP 
presence is strong at these points. Uncleaved caspase-3, also known as procaspase-3, 
follows a similar pattern as uncleaved PARP-- present in all samples and enhanced at 
the latter time points (Fig. 12).  Reduction in uncleaved caspase-3 is seen at 18 and 24h 
with the highest dosage of exosomes. Cleavage of caspase-3 (which indicates 
apoptosis) is not evident for either subunit in 3 and 6h, but is seen at the 18, 24h time 
points, with both subunits present in several of the titrations (10, 20, 50 g/mL).  Neither 
cleaved subunit is evident in the 100 g/mL dose at these time points.  To further 
differentiate apoptosis from necrosis, DNA was extracted from cocultured cells, 




genomic DNA) and electrophoresed on an agarose gel to detect fragmentation, which 
indicates apoptosis (Fig. 13). Ramos cells cultured for 3, 6,18, 24h without exosomes do 
not exhibit DNA fragmentation. In the case of Ramos cells cocultured with exosomes for 
3 and 6 h, apoptosis is seen with the highest concentration of exosomes, with 
diminishing effects as the exosome titration decreases. However, in the 18 and 24h 
exosome cocultures, apoptosis is strongly detected at both 100 and 50 g/mL, with 
diminishing effects in the lower doses. 
 To address potential mechanisms of apoptotic induction in B cells by TDE, 
culture (UL124, UL-OY) and ascites-derived exosomes were isolated, solubilized, and 
subjected to electrophoresis and subsequent Western blot, utilizing FasL (for culture-
derived) and CD40L (for ascites-derived) detection antibodies (Fig. 14).  Of the two 
culture-derived samples, UL-124 indicated presence of both membrane and soluble 
FasL in all amounts, with greater expression of the membrane isoform in the higher 
quantities of protein. Expression of CD40L was seen in all ascites-derived exosomes 
analyzed. The presence of these molecules suggest potential mechanisms for exosome 
communication with B cells, and subsequent induction of apoptosis 
Coculture with TDE Enhances Particular Molecules 
 To further evaluate the direct effects of TDE on B cells, 24h coculture 
supernatant (T24) and the corresponding control (C24) was analyzed for comparative 
expression of various molecules using a human cytokine array (Fig. 15).  The expression 
of several molecules appeared to be enhanced in the exosome-treated sample, with 
three (soluble intercellular adhesion molecule (sICAM-1), IL-16, and plasminogen 
activator inhibitor-1 (PAI-1)) exhibiting a greater than 2 –fold difference in comparison to 








 As a collaborator in the effector immune response, mature B cells employ a 
number of tactics in recognizing and destroying microorganisms. They can produce 
antibodies, express various molecules (e.g. costimulatory molecules [307],  toll-like 
receptors (TLRs) [308, 309]) to enhance the promotion of antibody function [310], act as 
antigen presenting cells [311], produce inflammatory cytokines and reactive oxygen 
intermediates [312], and release exosomes which display exosomal proteins and B cell 
surface antigens [313] which are believed to enhance cognate interaction with CD4+T 
and subsequent B cell activation and exosome production [314].  Although the specific 
function of B cell exosomes has yet to be fully elucidated, the roles of tumor-derived 
exosomes/microvesicles in intercellular communication are rapidly emerging.  One such 
role is the induction of apoptosis of effector cells to facilitate immune escape and 
mediate tumor progression. Human colorectal cells were reported to release 
microvesicles containing FasL and TRAIL which induced apoptosis in activated CD8+T 
[111]. In a study investigating the role of immunosuppression in glioblastoma patients,  
glioblastoma-derived exosomes were found to induce apoptosis in T cells via the Fas 
signaling pathway [315].  Correspondingly, tumor-derived microvesicles isolated from the 
sera of melanoma and head and neck squamous cell carcinoma patients promoted the 
expansion of regulatory T cells by inducing apoptosis of CD8+T cells [316].  This 
investigation seeks to gain a clearer understanding of the role of TDE in the ovarian 
cancer humoral response, by analyzing the effects of TDE on the B cell. Because our 
TDE express CD40L, our initial hypothesis was that TDE could activate the B cell 
(possibly via CD40 ligation) thereby initiating the production of antibodies and potentially 
the induction of antibody class switch. A series of preliminary experiments post coculture 




may not be likely due to the undetected phosphorylation of molecules in the CD40L 
signaling pathway.   However, upon extension of culture times (3, 6, 18, 24h) it became 
apparent through cell counts for viability and culture appearance post incubation that an 
effect was taking place. Cells cocultured with UL-124 TDE (100 g/mL) displayed a 
shrunken morphology.  Furthermore, RTPCR analysis (data not shown) revealed a 
reduction in gene expression in the TDE-treated cells in all housekeeping genes tested   
(-actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 2-microglobulin, 
hypoxanthine-guanine phosphoribosyltransferase (HPRT)), which suggested a potential 
issue with toxicity. In order to distinguish whether these cellular alterations were the 
result of apoptosis or necrosis, several mechanisms were employed.  First, cellular 
lysates from the cocultures were obtained, subjected to Western blot and probed with 
known apoptotic markers, caspase-3 and PARP. Apoptosis (programmed cell death) is 
the active, controlled intracellular disassembly by which the cell coordinates self-
destruction [317] without inducing inflammation or damage to neighboring cells [318].  In 
apoptosis, activation of initiator caspases (caspase-8 and 9) result in the activation of 
executioner caspases (e.g. caspase-3) which can result in cleavage of downstream 
substrates including poly-ADP Ribose polymerase (PARP) [317].  PARP, a DNA-binding 
enzyme, transfers poly ADP-ribose polymers to DNA strand breaks [319] to assist in 
DNA stability and repair [320].  In facilitation of apoptosis, cleaved caspase-3 can cleave 
the 116 kDa PARP into 89 and 24 kDa fragments, thereby inhibiting the catalytic activity 
of PARP [321].   This inhibition results in lack of repair to DNA strand breaks and 
activation of endogenous Ca2+ and Mg2+ endonucleases that promote DNA degradation, 
producing DNA fragments 180-200 base pairs in length [322].  In our study, treating B 
cells with ovarian cancer exosomes (in a dose-dependent manner) not only induced 




in fragmentation of DNA, particularly with the higher concentrations of exosomes 
(100g/mL at all time points and 50 g/mL at the latter time points, 18 and 24 h).  
Collectively, these data implicate ovarian TDE as an inducer of apoptosis in B cells. The 
induction of apoptosis in human immune effector cells by tumor-derived 
exosomes/microvesicles has been documented in several different cancers, each 
mediating the process in various ways. One of the common mechanisms of mediation is 
through the release of exosomes that contain apoptosis-induction signal molecules, such 
as FasL or TRAIL. Studies have implicated exosome/microvesicle associated FasL as 
the signal for apoptotic induction in activated T cells [323], in peripheral blood 
mononuclear cells [324], and CD8+T cells [315, 325].  FasL is a tumor necrosis factor 
receptor (TNF-R) family cytokine [326] which can be synthesized in soluble or 
membrane-bound form, the latter shown to be more active than the soluble form in 
apoptotic induction of primary T cells [327, 328] and hepatocytes [329].  Mechanistically, 
FasL engages and induces trimerization of its cognate receptor, Fas [330], resulting in 
Fas activation and recruitment of adaptor proteins (i.e. Fas-associated death domain—
FADD) to its cytoplasmic death domain to form a death receptor-induced signaling 
complex (DISC) [331, 332].  Procaspase-8 is recruited into the DISC [333] and is 
proteolytically activated to caspase-8 which activates downstream effector caspases, 
like caspase-3 [334], resulting in cleavage of substrates including PARP and the inhibitor 
of caspase-activated DNase (ICAD) [335]. Cleavage of ICAD releases caspase-
activated DNase (CAD) which cleaves the chromosomal DNA which is responsible for 
the DNA fragmentation detected during apoptosis [336].  In analysis of our UL-124 
culture-derived exosomes used throughout this study, the expression of both soluble and 
membrane-bound FasL suggests that these exosomes may be activating the Fas/FasL 
pathway in the induction of B cell apoptosis.  A plausible yet equally important 




pathway.  CD40 is a TNF-R family member transmembrane receptor [337] that is 
trimerized and activated upon engagement by its cognate ligand, CD40L [338]. Under 
normal conditions in conjunction with signals from the engaged B cell receptor (BCR), 
CD40 ligation triggers B cell activation, characterized by increases in tyrosine kinase 
activity [339] and DNA synthesis [340], expression of costimulatory molecules [341] and 
transcription factors [342], and immunoglobulin class switch [343].  Correspondingly, the 
engagement of these receptors have been shown to induce Fas expression on the B cell 
surface, with greater amounts of Fas when both receptors were ligated [344].  In spite of 
the expression of fewer Fas molecules, murine B cells with ligated CD40 without  BCR 
engagement are more sensitive to apoptosis [345, 346].  Likewise, apoptotic induction 
via upregulation of Fas by CD40 ligation has been corroborated in normal and malignant 
human B cells [347]. With this in mind, we propose that the exosome-associated FasL 
and CD40L ligate their respective receptors on the B cell to mediate apoptosis of the B 
cell as a mechanism of modulating the humoral immune response.  Further analysis is 
needed to verify the contributions of CD40L and FasL in the mediation of B cell 
apoptosis. Additional investigation could include coincubation of blocking antibodies to 
CD40L and FasL with TDE or to their respective receptors with the B cells prior to 
coculture.   Post coculture, analysis of apoptotic induction would implicate exosome-
associated CD40L as the activator of the B cell to upregulate Fas expression and 
exosome-associated FasL as the extrinsic mechanism that induces apoptosis. 
 To further investigate potential contributors to the TDE-mediated apoptosis of B 
cells, the supernatants from the 24h control (C24) and treated (T24, highest 
concentration) cultures were analyzed for the presence of soluble mediators.  Analyses 
revealed a greater than 2-fold expression of three molecules (PAI-1, IL-16, sICAM-1) in 
the exosome- treated sample in comparison to the non-treated control. A closer 




escape of malignant cells, either through mechanisms that assist with evasion or 
promotion of apoptosis, or progression of the tumor.  PAI-1 is a key inhibitor of 
plasminogen activators (serine proteases responsible for plasmin production which leads 
to fibrinolysis [348] and activation of matrix metalloproteinases and growth factors [349]).  
PAI-1 subsequently inhibits plasmin production, thereby preventing these responses and 
affecting cell migration [349].  The expression of PAI-1 has been shown to be elevated in 
different cancers [350, 351], and its enhanced presence is linked to tumor cell survival 
[351-353].  In the promotion of apoptosis, PAI-1 binds to vitronectin (extracellular 
glycoprotein),which interferes with cellular adhesion by blocking cell receptors and 
integrins [354].  B cells display the vitronectin receptor (v3) [355, 356] which plays a 
role in mediating phagocytosis of cells that are undergoing apoptosis [357].  In 
consideration of the apoptotic induction of B cells by TDE, we propose that in the tumor 
microenvironment, PAI-1 may allow the exosomes to interact with vitronectin in an 
attempt to block B cell interaction, which would induce apoptosis of the B cell because of 
its inability to adhere. Because the vitronectin receptor on the B cell surface would 
remain unbound, it would act as a signal to phagocytes to remove the B cells from the 
microenvironment. We believe that PAI-1 is also associated with the exosomes, which 
the tumor cell would release as a means of interacting with B cells and other effector 
cells.  IL-16 is an immunomodulatory cytokine typically released at the site of 
inflammation [358] as a chemoattractant for eosinophils, monocytes, and T cells [359].   
Synthesized in its precursor form (pro IL-16), this precursor is cleaved by caspase-3  to 
release the active form, IL-16 [358] which is secreted by epithelial, mesenchymal, and a 
number of immune cell types [360], including B cells [361]. In the context of cancer, 
documented levels of IL-16 are elevated in the serum of cancer patients [362] and 
correlate with the progression of disease [363].  Furthermore, enhancements in IL-16 




indicated that spontaneous activation of caspase-3, resulted in apoptosis and 
extracellular increases in IL-16 [360]  In this study, greater than 2-fold expression of IL-
16 was seen in the TDE-treated sample in comparison to the control. We propose that 
as the TDE interact with the B cells through CD40L and FasL to activate apoptotic 
pathways, they activate caspase-3 which is able to cleave pro IL-16 in the B cell, thereby 
allowing the release of IL-16 into the extracellular environment. This released IL-16 
could be instrumental in recruiting a number of immune cells to facilitate apoptotic B cell 
clearance.  ICAM-1 is a membrane glycoprotein expressed on a number of cells, 
including endothelial cells and B cells, that mediates cell-matrix and cell-cell interactions 
by binding with its ligand, leukocyte function-associated antigen-1 (LFA-1) [364].  ICAM-
1 also exists in soluble form, sICAM-1, a product of proteolytic cleavage of the 
membrane-bound version [365, 366].  Correlation between heightened serum levels of 
sICAM-1 and tumor progression and/or poor prognosis is evidenced in various cancers.  
Increases in sICAM-1 in colorectal cancer [367] and melanoma [368] were found to be 
linked to tumor progression.  In studies of human melanoma cell lines, sICAM-1 was 
found to obstruct the interactions between T cells and the tumor cells [369] and to block 
the tumor from the cytotoxic effects of NK cells [370].  Breast cancer patients were 
documented to have increased levels of sICAM-1 in their sera correlating with tumor 
progression and poor prognosis [371, 372].  In cancer patients, sICAM-1 is thought to 
derive from the cancer cells themselves or from some component of the tumor 
microenvironment [371, 373, 374].  Investigation of the efficacy of prostate cancer 
exosome-associated ICAM-1 revealed the presence of both membrane-bound and 
soluble forms, but the sICAM-1 was shown to be less effective in interacting with LFA-1 
and in modulating the immune response [375].  In our studies, we propose that the 
increases in sICAM-1 in our TDE-treated samples indicate its association with the 




immunosuppressive mechanism that prevents interaction between the tumor cell target 
and the cytotoxic effector [376].  The ovarian tumor may preferentially release  
exosomes with sICAM-1 associated with them in an attempt to subvert interaction with 


















Figure 10:  Percentage of cell death in Ramos cells cocultured with patient tumor-derived exosomes.  The percentage 
of dead cells in culture as determined by trypan blue staining.  Ramos B cells were cocultured with patient UL-124 exosomes 
for different lengths of time (3, 6, 18, 24 h) and at different exosome doses (10, 20, 50, 100 g/mL). C (control, untreated), T 
(treated with exosomes). The number following the letter indicates the time point (h). The number following the time point 
indicates the exosome concentration (g/mL). Asterisks indicate significance levels of t-test control comparisons with treated 
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Figure 11: Coculture of patient tumor-derived exosomes enhance presence of apoptotic 
marker, PARP.  Western blot analysis of PARP and PARP cleavage in total cell lysates from 3, 6, 
18 and 24h cocultures of Ramos cells with UL-124 OC exosomes (10-100 g/mL).  Densitometric 
quantification of the ratio of PARP (cleaved and uncleaved) to -actin is shown. Data represents 3 
independent experiments with similar results.  























Figure 12: Coculture of patient tumor-derived exosomes enhance presence of apoptotic marker, 
caspase-3.  Western blot analysis of caspase-3 and caspase-3 cleavage in total cell lysates from 3, 6, 
18 and 24h cocultures of Ramos cells with UL-124 OC exosomes (10-100 g/mL).  Densitometric 
quantification of the ratio of caspase-3 (cleaved isoforms and uncleaved) to -actin is shown. Data 
represents 3 independent experiments with similar results. 
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Figure 13:  DNA fragmentation analysis of B cell apoptosis induced by coculture with TDE. Ramos B cells were 
cocultured for 3, 6, 18, and 24h with tumor-derived exosomes at concentrations ranging from 10-100 g/mL. Apoptosis is not 
detected in control samples (C3, C6, C18, C24) while exosome-treated samples (T) undergo apoptosis to varying degrees. 
The greatest fragmentation is seen with the higher concentrations of exosomes (T 100) with gradual decreases as exosome 
concentration decreases.  C (control), T( treated with exosomes). Number following C or T represents length of time for 
coculture (3, 6, 18, or 24 h). Numbers (10, 20, 50,100) represent concentration of exosomes added in g/mL.  PC represents 





































































































































































Figure 14:  Analysis of in vitro and in vivo derived-exosomes reveal presence of potential activators of B cell 
apoptosis.   
A) Western blot of UL-124 (1) and UL-OY (2) culture-derived patient exosomes ( UL-124:1; UL-OY: 2) using varying amounts  
of exosomal protein (45, 50, 55, 60 g/lane)  reveal presence of  both soluble (26 kDa) and  membrane-bound  (40 kDa) 
forms of FasL in the UL-124 sample.  B) Western blot of OC patient-derived ascites exosomes (UL-472, 309, 316, 224) reveal 
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Figure 15:  Molecule induction in Ramos B cells cocultured for 24h with tumor-
derived exosomes.  Analysis of coculture supernatant using a human antibody array 












CONCLUSION AND SIGNIFICANCE OF WORK 
 
 In countless studies, tumor-derived exosomes (TDE) demonstrate their ability to 
orchestrate communication between the tumor cell and the microenvironment in order to 
facilitate antitumor and protumor responses.  Previous investigations have analyzed 
TDE interactions with a number of immune cells including T cells, myeloid-derived 
suppressor cells, and dendritic cells, but little to no investigation is evident on the effects 
of TDE on B cells. This study began to explore the role that TDE may play in the efficacy 
of the humoral immune response by analyzing the exosome-associated humoral 
antitumor response and the impact of exosomes on humoral modulation through their 
interaction with B cells.  In the ovarian cancer framework, humoral responses are 
evident by the presence of enhanced  IgG in the circulation, yet the cancer continues on 
its aggressive course, all while presenting non-obvious symptoms. The presentation of 
symptoms that mimic other conditions and/or the lack of obvious symptoms contribute to 
the latent diagnosis of ovarian cancer.  
Utilizing human ovarian cancer as the model cancer system, ovarian TDE were 
found to display some of the same antigenic proteins as their parent cells, and bound 
immunoreactive IgG, primarily of the IgG1 and IgG2 subclasses. These findings indicate 
that TDE may express immunogenic antigen as a mechanism to divert the humoral 
antitumor response away from the tumor and towards itself. In the diversion of the 
response, IgG1, which is one of the complement-fixing, opsonizing antibodies important 




antitumor response.  Additionally, IgG2 antibodies are produced and also bind to the 
antigen on the exosome, which is believed  to block the opsonization, phagocytosis, and 
antibody-dependent cell cytotoxicity (ADCC) of the IgG1 [281].  Therefore, the presence 
of IgG2 may counteract the immune response against the exosome-associated antigen, 
resulting in a decreased antitumor response, which would further benefit the ovarian 
cancer cell by allowing it to progress.  Additionally, ovarian TDE were found to induce B 
cell apoptosis and promote increases in PAI-1, IL-16, and sICAM-1 to assist in 
promoting the survival of the ovarian tumor.  Overall, this study indicates that ovarian 
TDE are able to modulate the humoral immune response at the anti- and protumorigenic 
levels through direct effects on the exosomes, and the effects of the exosomes on the B 
cells (Fig 16). 
Taking all of these factors into consideration, the hyperexpressed but seemingly 
ineffective IgG in the ovarian cancer patient sera may be a direct result of this battle 
between protumorigenic and antitumorogenic responses mediated by ovarian TDE.  
Further biochemical analysis of this exosome-associated IgG may provide additional 
insight on potential structural modifications induced which could further interfere with the 
ability of IgG to adequately mediate an immune response.  Much remains to be defined 
and elucidated regarding the mechanisms of the host immune response to ovarian 
cancer. However, this study does provide perspective on a different facet of the immune 
response which has previously been unexplored.  Further consideration of the humoral 
immune response component of ovarian cancer may shed some light on this enigmatic 
disease and contribute an additional strategy to be utilized in the fight against ovarian 















Figure 16:  Proposed mechanism of TDE modulation in the ovarian cancer humoral response.  Immunogenic 
antigen expressed by the ovarian tumor induces a humoral antitumor response, resulting in the production of 
immunoreactive antibodies. The ovarian tumor releases TDE which may also express immunogenic antigen, thereby 
allowing the secreted antitumor antibodies to bind to both the tumor and the TDE. Intercommunication between TDE 










antitumor antibodies. In the interaction between B cells and TDE, relative expression of plasminogen activator 
inhibitor-1 (PAI-1), IL-16, and soluble intercellular adhesion molecule-1 (sICAM-1) is enhanced to potentially contribute 
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Graduate Research Assistant/M.S. Developmental Biology, Mississippi State 
University, Mississippi State, MS. 1996-1999. 
 Conducted experiments to analyze melanophore differentiation in embryonic 
zebrafish under normal and treated conditions 
 Maintained an in-house adult zebrafish colony (150+ zebrafish) for breeding 
 
Research Assistant. Emergency Department, Children’s Hospital of Alabama, 
University of Alabama at Birmingham, Birmingham, AL.  Summer 1993. 
 Co-conducted patient satisfaction surveys (via parents) on the quality and 
satisfaction of care received in the emergency department 
 Co-constructed, designed, and updated informational pamphlets on the 
emergency department’s triage system 
 
Research Assistant. Anesthesia Research Department, University of Alabama at 
Birmingham, Birmingham, AL.  Summer 1992. 
 Conducted experiments on surface tension of artificial surfactant 
 
   
TEACHING SERVICE ACTIVITIES  
 
Instructor for Summer Minority Science Workshop. Oak Ridge Branch Campus, 
Roane State Community College, Oak Ridge, TN.  2002-2007. 
 Designed and facilitated the biology component of a week-long workshop for 
local students (middle school-high school) to generate greater interest and 







Assistant Facilitator for Freshman Experience. Cumberland County Campus, Roane 
State Community College, Crossville, TN.  Fall 2003-2004. 
 Designed and facilitated activities to assist incoming freshmen with 
acclimation to the community college environment 
 
Campus Tour Assistant. Cumberland County Campus, Roane State Community 
College, Crossville, TN.  2002-2005. 
 Conducted tours of the biology lab for local students (middle school-high 
school)  
 
Instructor For GearUP GradKids Summer Academy. Scott County Campus, Roane 
State Community College, Huntsville, TN.  2003. 
 Conducted a one-day science experience for students participating in 
GearUp GradKids, a federally-funded program designed to encourage Scott 
and Cocke county (TN) students to pursue higher education. 
 
Biology Textbook Reviewer 
 Krough, D.  Biology: A Guide to the Natural World. 3rd ed. Prentiss Hall, 
2004. 
  Complete text 
 Raven, P.H., Johnson, G.B., Losos, J. and S. Singer. Biology. 7th ed. 
McGraw-Hill, 2004. 
  3-chapter review 
 Russell, P.J., Wolfe, S.L.,  Starr, C.,  Hertz, P.E. and B. McMillan.  Biology: 
The Dynamic Science. Brooks-Cole, 2007. 
  3-chapters plus preface 
  
Co-Facilitator for Gateway Workshop. Roane County Campus, Roane State 
Community College, Harriman, TN.  April 2001. 
 Co-designed and facilitated a week-long workshop for local high school 
science teachers to assist them in preparing their students for the biology 




Teacher Preparation Grant Workshop (Pellissippi State Technical Community 
College (PSTCC), Knoxville, TN):  May 2006, February 2007, October 2007, 
February 2008, May 2008 
 NSF funded Partnership grant (TBR-TPP) with PSTCC and TBR Schools in East 
TN 
 Includes reviewing of, making changes to, and development of new courses 
needed for Elementary Education degree (K-6) and Associates of Science in 
Teaching (AST) degree 
 
WebCT Academy (RSCC): May 2004, 2005 
 In depth look at the purpose, capabilities, and use of WebCT in course 





Day at Mercer (Atlanta, GA): March 2003, 2005 
 One-day workshop providing Pharmacy and Pharmacy Tech advisors with 
information about Mercer University Southern School of Pharmacy 
 
NCSI Summer Workshop (High Point, NC):  July 2003 
 Follow-up workshop to SC2002 
 
SC2002 Education Program (Baltimore, MD): November 2002 
 Supercomputing Education Program focusing on use of computer visualization 




Integrated Programs in Biomedical Sciences (IPIBS) Fellowship. University of 
Louisville, 2009-2011. 
 
Technology Access Fee (TAF) Fund Award. Roane State Community College, 16-bay 
Mobile Cart (Dell wireless laptops), 2003. 
 
Institutional Effectiveness Planning (IEP) Fund Award. Roane State Community 
College, Dell laptop (for instructor), lab projector, ADAM Interactive Anatomy Software, 
and projection screen, 2001. 
 
Departmental Travel Award. Mississippi State University. Association of Southeastern 
Biologists (ASB) meeting. Wilmington, NC, 1999. 
 
Departmental Travel Award. Mississippi State University. Pan American Society for 
Pigment Cell Research (PASPCR) meeting. Snowmass, CO, 1998. 
 
COMMITTEES AND ORGANIZATIONS 
 
American Association for Cancer Research (AACR). Member. 2012-present. 
 
American Society for Exosomes and Microvesicles (ASEMV). Member. 2013. 
 
Microbiology and Immunology Student Organization (MISO), Member. University of 
Louisville, 2009-present. 
 
Black Biomedical Graduate Student Organization (BBGSO), Vice-President, 
Secretary. University of Louisville, 2010-present. 
 
Anatomical Sciences and Neurobiology Department (ASNB) Chair Search 





Math/Science Faculty Interview Committee. Roane State Community College, 2005-
2008. 
 
President Search Committee, Faculty Representative. Roane State Community 
College, 2005. 
 
Pan-American Society for Pigment Cell Research (PASPCR).  Member. 1998-1999. 
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